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INTRODUCTION 
              Siddha system is an ancient system of medicine and was found by Siddhars who 
have attained siddhi (spiritual perfection). Siddhars who really discovered something for the 
good of humanity are seers, thinkers and men of action. They are creative genius. Siddha 
system plays a wide ranged role in the field of pediatrics. It ensures the health of the 
children with its astonishing herbal formulations right from their conception, to prevent the 
illness. Children‘s health reflects the Nation‘s health and wealth and they are the most 
vulnerable group in the society. They can become ill easier since they aren‘t built with a 
good immune system and they are exposed to several pathogens from the surrounding 
environment. 
              Psoriasis is a common, chronic inflammatory disorder that affects the skin, nails & 
joints of ~ 2.0 % - 3.5 % of the general population with a strong genetic basis. Childhood 
psoriasis is a well recognized entity but its true prevalence is not known. Psoriasis begins in 
childhood in approximately one – third of the cases. Children accounted for 12.5 % of total 
psoriasis over a period of 13 years. Age of onset ranged from 4 days to 14 years, male and 
female incidence was equal & plaque type of psoriasis was the most common type in 
children. 
 As much as 40 % of adult patients with psoriasis have reported manifestations of 
this condition in childhood with at least one – third of the patients demonstrating features of 
psoriasis before the age of 16.1 years.   
             When psoriasis starts in childhood it has more adverse implications. Extensive 
research has focused on the comorbidities associated with psoriasis and its effects on the 
quality of life (QOL) of the child and the adult caretaker. Children suffering from psoriasis 
have a higher prevalence of obesity, diabetes mellitus, hypertension, juvenile arthritis, 
psychiatric diseases.  Psoriasis can be a life – affecting disease with a potentially profound 
impact on physical, emotional & social functioning & overall QOL in children.           
          Siddha  system  describes  4448  diseases  and  its  treatment. The clinical features of 
Kaalanjaga padai may be correlated to Psoriasis as described in Modern science. Psoriasis is 
a lifelong disorder subject to unpredictable remissions and relapses. Single episodes are 
uncommon and in the most frequent variety an episode in the childhood is followed by a 
series of attacks, each lasting approximately for 3 – 6 months. 
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The visitation of children with psoriasis has increased considerably from the past 
few years in National Institute of Siddha. Patients suffering from Psoriasis are facing  much 
social stigma than other dermatological problems. 
So the author is obliged to carry out this study to evaluvate the therapeutic 
effectiveness of the Amukkura Chooranam and Vettiver Thylam cited in Brahmamuni 
Karukkadai Soothiram 380 and Aathma Rakshamritham Ennum Vaidya Sara Sangraham 
respectively for this disease. Drugs with hot potency have the action of curing skin disease. 
Hence trial medicine which has pungent and astringement taste with hot potency was 
selected for this disease. 
Siddha medicine is one which cures ailment of body, mind, one which prevents 
recurrence of ailment and one which makes us attain immortality. So in the view of long 
term outlook regarding the treatment plan in the paediatric group the author has chosen the 
present study. 
Since selected subjects are in vulnerable group (i.e) that is paediatric the choosen 
drug internal as well as external are purely herbal. In modern system of Medicine the 
treatment for almost all types of paediatric psoriasis cases will be either steroids or UV 
therapy (there are chances of convertion of psoriasis to carcinomatous condition if done 
more than 30 sittings ) which has got severe side effects . So if we are able to treat such a 
condition with pure herbal drug will be a great achievement, since the severity of the illness 
will affect body, mind, and quality of living. So a cost effective and drug with a lesser 
adverse effect is the need of the hour. 
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AIM AND OBJECTIVE 
 
 AIM: 
 
The aim of the present clinical study is TO EVALUATE THE EFFICACY OF 
AMUKKARA CHOORANAM (INTERNAL) AND VETTIVER THYLAM (EXTERNAL) 
IN THE TREATMENT OF KALANJAGAPADAI (PSORIASIS)  IN CHILDREN.   
 
OBJECTIVES: 
 
Primary objective: 
 
To evaluate the efficacy of  AMUKKARA CHOORANAM (Internal) and 
VETTIVER THYLAM (External) in the treatment of KALANJAGA PADAI (PSORIASIS)  
in children. 
 
Secondary objective: 
To study occurrence of new lesion, anywhere else in the body after intake of trial 
medicine. 
 
 Also, 
 To collect the authorial measures and literature reviews of KALANJAGA 
PADAI in ancient siddha and modern literatures. 
 Have an idea of the incidence of the disease with regard to age, sex, 
precipitating factors socio economic status, food, kaalam etc. 
 To explore the efficacy of siddhar‘s diagnostic principles. 
 To utilize the modern investigation methods to confirm the diagnosis and 
prognosis. 
 To study the biochemical and physiochemical analysis of the trial drug 
 To assess the response of lesion with respect to 
                                            Seasonal variation 
        Stress  
        Dietary modification etc. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT OF DISEASE (KAALANJAGA PADAI) 
          In siddha system, skin diseases are brought under ―kuttam‖, kuttam means 
cutaneous affections in general, the term used for various skin diseases. 
DEFINITION OF SKIN DISEASES: 
             Skin diseases may appear all over the body on a sudden or gradually spreads and                     
affects the nerves, blood vessels, mucus membrane etc. The affected part may have 
increased or decreased sensitiveness and inflammation. Skin becomes glossy and thick red 
or yellowish white patches with various size. 
                        It is marked by 
 Itching 
 Burning sensation 
 Blisters 
 Perforating ulcers 
 FACTS OF SKIN DISEASES: 
1. It is a diseases believed due to a reflection of one‘s previous births (karma) 
2. Some authors of Indian medical science attribute the origin of this disease to 
several pathological causes. Such as,  
 Venereal diseases 
 Syphilis 
 Ring worm 
 Snake bite 
 Poisonous insects bite or sting 
 Infection 
 Inheritance 
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AETIOLOGY: 
    The siddha literature explain the causes of kuttam as mentioned  below 
 In the text Yugimuni 800 
―tpsk;gNt kpFe;jc\; ze;jd; dhYk; 
     kpFe;j rPjsj;jhY kow;rp ahYk; 
tsk;gNt ke;jj;jhy; the;jpahYk; 
     kfj;jhd ngz;NzhL kUtyhYk; 
fpsk;gNt fpNyrq;fs; kpFj yhYk; 
     nfbahd Tuf;fq;fs; ilj jhYk; 
jsk;gNt kapUfw;fs; jtpL kz;fs; 
     rhjj;jpw; gUfyhy;kpf;Fq; F\;lk;‖ 
Excessive heat and cold, laziness, sleep in day time, sexual indulgence robbery etc. 
These habits are prominent among the factors which lower the immune mechanism of the 
body (Udalvanmai) and make the body liable to disease. Added to the above, excessive 
intake of food items which are hard to digest , imbalanced diet  and vomiting due to 
indigestion , food contaminated with stone and hair , chronic mental depression , intention 
to spoil others , greed , abusing God and elderly people , neglecting orphans and beggars , 
cursing the elders would also affect the body and mind disturbing the mechanism of the 
body.     
 In Thirumoolar Vaithiyam 
―tpahjpapy; %thWtpsq;fpa Fl;lq;Nfs; 
Rahjpf; fpue;jp Roy; Nkfj;jh yhWk; 
gahjp kz;Zsg; gy tz;bdh nyl;Lk;  
ePahjp GOehyha; epd;wjpf; Fl;lNk‖  
 
Six types of skin diseases are caused by venereal disease 
Eight types of skin diseases are caused by insect bites 
Four types of skin diseases are caused by worm infestations  
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 In Guru Naadi Nool 
  ―fpUkpahy; te;j Njhlk; ngUfTz;L 
Nfl;fp yjd; gphpTjid fpukkhfg; 
GOf;fb Nghy; fhZkJ fpUkpahNy 
nrUkp tUk; gTj;jpuq;fs;  fpUkpahNy  
Njfkjpy; nrhwpf;Fl;lk; fpUkpahNy  
JUkp tUk; RNuhzpjq; ; fpUkpahNy  
#l;rKld; fphpirg;ghy; njhopy; nra;tPNu‖. 
As per Guru Naadi Nool text, the skin disease is caused by worm infestations. 
       In the text book Siddha Maruthuvam Sirappu , the cause of kuttam is due to 
 Unknown etiology 
 Genetic cause 
         The text Agasthiyar Paripooranam – 400 describes the (Kanma Varalaru) as a 
causative factor for this disease 
  ―gotpidahy; tp\g;G+r;rp fbj;j Njh\k; 
           ghjfHf;F xU ehSk; jPHtjpy;iy 
cstpidahy; Y}lhgpf nfhs;s te;j 
           cz;ikaJ mwpahky;%Hf;fQ; nra;thH 
fstpidAe; jPHtjpy;iy fbdnkj;j 
           fUizAs;s G+uzj;jpy; fz;fhl;rp 
mltpid  ePfhZKd;nd mfyr; nrhy;yp 
           milahsk; tpuy; FWF kpd;dq;fNfNs‖. 
  ―tpuy;FWFq;fhy jpkpUk; tp\k; NghNyWk; 
           Nka;aOe;Je; jiy ROYk; mtSf;Fk; Nkdp 
gukhd Njfnky;yhe; jbj;J tPq;Fk; 
           ghjnky;yhk; ntbj;Jkpf;FGz;Z fhZk; 
rurKld; nrhwp fug;ghd; gzk; Nghy; NjhZk;  
           re;ijahNk tpe;ijnfLj; jbj;J tPq;Fk; 
ghUyfp ype;Neha;f;F kUjPahNj 
           ey;Nyhiug; gopjpj Fl;lq;fd;dkhNk‖. 
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In  Agathiyar Paripooranam 400 it has been mentioned that  diseases which are 
caused due to sins committed in the previous birth will be cured only if Kanmam is 
expiated. Siddhar Agathiyar mentioned that Kanmam (Genetic predisposition) is the main 
cause for kuttam in the text Kanma Kandam as follows,  
―NrHe;j Fl;lnkhL FiwNeha;fs; 
     NrjpNfs; kyuhj tUk;G nfha;jy; 
jhhpe;j rPH nre;J tijfs; nra;jy; 
       jha; je;ij kdJ nehe;J Nuhfe;jhNd 
jhndd;w  nja;tTUj; jidopj;jy; 
       rhHthd nghpNahHfs; jikg; gopj;jy; 
fhndd;w ee;jtdk; g+r;nrbfs; ntl;ly;  
       fUkklh rhPuj;jpw; fhR NghNy  
A+ndd;w Tlk;ngy;yhk; nkhl;L nkhl;lh 
       Ald; ntSj;J FiwNahAjpuQ; rpe;Jk;  
thndd;w fUkq;fs; jPHg;gjw;F 
      tiunad;W nrhy;Ntd; Nfs; ee;jtd;ikNa‖. 
 
 Plucking the flower buds 
 Cruelty to animals 
 Destroying statue of god  
 Abuse elderly people 
 Destroying forests and gardens  
SIGNS AND SYMPTOMS: 
 The predominant symptoms are  
 Roughness of skin 
 Itching sensation 
 Black color of the blood 
 Rapid growth and spread of ulcers 
CLASSIFICATION OF KUTTAM:   
According to Thiru T.V. SambasivamPillai there are 18 types of Kuttam, as listed 
below: 
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1. Neerkuttam  - Leprosy with serous exudation 
2. Venkuttam  - White Leprosy  
3. SoriKuttam  - Psoriasis   
4. Karunkuttam  - Black Leprosy 
5. Perumkuttam  - True Leprosy  
6. Senkuttam  - Macular Leprosy   
7. Pori kuttam  - Leprosy with Granules  
8. Virikuttam  - Leprosy with Fissures 
9. Yerikuttam  - Leprosy with burning sensation  
10. Viral kuraikuttam - Lepramutilans  
11. Sadaikuttam  - Leprosy with confluent ulcers  
12. Yaanaikuttam - Thick skinned Leprosy  
13. Thimirkuttam - Anesthetic Leprosy  
14. Viranakuttam - Ulcerated Leprosy  
15. Kaaikuttam  - Nodular Leprosy 
16. Azhikuttam  - A form with sloughing ulcers  
17. Kirumikuttam - Leprosy with microbes  
18. Aarakuttam  - Incurable Leprosy   
 
Classification by Dhanvanthiri: 
   ―thjgpj;jr; rpNyw;gdj;jpd; thjNuhfe; jhnddpDk; 
  jPJ Fl;lNkOe; jPUk; Fl;lk; gjpndhd;W 
  NkhJq;  Fl;lk; gjpndl;Lld;Nwha itapDw;gtKk; 
  Ngjf;FzK tpahjpapd Kd;gpwf;Fk;FzK Kiug;NgNd‖  
 
1. Kabala Kuttam 
2. Sarmeega Kuttam  
3. Kideepa Kuttam 
4. Mudhumba Kuttam  
5. Visharchiga Kuttam   
6. Mandalakira Kuttam  
7. Aguvai Kuttam   
8. Alasa Kuttam 
9. Thathru Kuttam   
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10. Pundareegha Kuttam  
11. Bama Kuttam  
12. Kaghanandhi Kuttam   
13. Sithma Kuttam  
14. Vibadhiga Kuttam  
15. Sadhariga Kuttam  
16. Vispodaga Kuttam  
17. Sarmathala Kuttam   
18. Ven Kuttam   
Classification according to Yugi Muni Vaidhya Chinthamani : 
   ―Kj;jhFq; Fl;le;jhd; gjpndl;Lf;Fk; 
       Kdpahd A+fpehd; nrhy;yf; Nfsha; 
  Gj;jhFk; Gz;lhPf Fl;lj; NjhL 
       ngUFfpd;w tpw;Nghlf F\;l khFk; 
  gj;jhfk; gukF\;lk; Nfrhp F\;lk; 
       ghpthd fHzFl;lk; rpFk Fl;lk; 
  Fl;lkhk; gug;ghpr Fl;l nkhL 
         Fbykhk; tprHr;rPf Fl;l khFk; 
  Tl;lkhk; itahjp Fl;l nkhL 
         kUtyhq; fPBgFl;lQ; rHk Njtk; 
  jpl;lkh Njj;jpUf; Fl;l NkhL 
        rpj;Jkh Fl;lQ;rh fhWFl;lk; 
  Jl;lkhQ; RNtjFl;le; jd;dh nlhf;fr; 
       Rak;ghd gjpndl;L Fl;l khr;Nr‖.  
 
1. Pundareegam - Padarthamarai  
2. Virpodagam - Koppulaperunoi  
3. Bamam  - Siranguperunoi  
4. Gajasarmam - Yaanaitholperunoi  
5. Karnam  - Kaadhuperunoi 
6. Sikuram  - Tholperunoi 
7. Krishnam  - Karuperunoi  
8. Avudhumbaram – Athikkaiperunoi 
9. Mandalam  - Valayaperunoi  
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10. Abarisam  - Valiperunoi  
11. Visharchigam – Soriperunoi 
12. Vibhadhigam - Senkuttam  
13. Sarmathalam - Tholvedippuperunoi  
14. Kidepam  - Pandritholperunoi  
15. Thethuru  - Thadippuperunoi  
16. Sithuma  - Naaperunoi 
17. Sadharu  - Puraiperunoi  
18. Suvedham  - Venkuttam   
 
 According to sage Yugi, Kuttam have been classified as 7 types as per alteration of 
three humors  
1) Valikuttam 
 2) Azhalkuttam 
 3) Iyyakuttam  
4) Valiiyyakuttam 
 5) Valiazhalkuttam 
 6) Azhaliyyakuttam  
7) Mukkutrakuttam   
 
 According to sage Yugi, ten types of kuttam are curable  
 1) Virpodagam  
2) Bamam  
3) Kajasarmam  
                        4) Kiruttinam  
5) Avuthumbaram 
 6) Thaththuru 
 7) Siththuma 
 8) Kideebam  
9) Satharu 
                       10) Sarumam  
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 According to sage Yugi, eight types of kuttam are uncurable  
1) Pundareegam 
 2) Karanam 
 3) Siguram 
 4) Mandalam  
5) Abarisam 
 6) Vasarchigam  
7) Vibathigam 
 8) Suvetham  
The clinical features of Virpodagakuttam, Sadharukuttam and Thethrukuttamare 
resemble as Kaalanjaga padai. 
tpw;Nghlff; Fl;lk; 
 ―GJikaha;r; rhPunkq;Fe; jpdTz; lhFk; 
       nghUntbaha;j; jpf;nfdj;jPf; nfhOe;J Nghy  
 nkJikaha; tpl;nlhpAk; ey;yghk;gpd;  
       tp\g;glk; Nghy; jbj;J ntSg;GkhFk;  
 RJikaha;kpff; nrhhpAQ;rptg;GkhFk;  
       J}f;fnkhL rQ;ryKk; kpf Tz; lhFk;  
fJikaha; Njhnyy;yhe; jbg;Gz;lhFk;  
       fdj;j tpw;Nghlfkhd Fl;le;jhNd ―.  
- A+fpKdp itj;jpa rpe;jhkzp 800 nra;As; 498  
 
     Characterized by elevated skin lesions with erythema and itching. Burning sensation 
will be present. These entities are associated with anxiety and despair. 
Njj;JU Fl;lk; :  
   ―rHke;jhd; rptg;ghf tl;lzpj;Jr; 
        ryitNghy; ntSf;FNk jpdTz;lhFk; 
    $Hke;jhd; NuhfkJ kpfTz;lhFk;  
    kapnuy;yhQ;RUz;LNk cz;ilahFk; 
    fh;ke;jhd; gpj;j Nrl;Lkkp Ff;Fk;  
         fhae;jhd; fjpj;JNk jpkpUz;lhFk; 
    jHke;jhd; rlnky;yh KjyhFk;  
         jhf;fhd Njj;JUf; F\;le;jhNd  
- A+fp Kdp itj;jpa rpe;jhkzp 800 nra;As; 511    
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  Annular erythematous lesions with whitish appearance, itching, oedema and curling 
of hairs are the characteristic clinical features in this disorder. 
rjhU Fl;lk; 
―rpj;jhdjz;bg;gha; uj;jtHzk; 
       nrOk;gr;ir nts;isaha;r; rptg;GkhFk; 
 vj;jhd nthpg;NghL jpdTkhFk; 
  vspjhd Nrj;Jkthj Jw;gj;jp 
   gj;jhd fuLfl;bg;Gz;ZkhFk; 
        ghk;G Njhy; Nghw;wpiue;JgUj;JfhZk; 
   ntj;jhd %f;NfhL fhj fd;dk; 
      kpfj;Jbg;ghQ; rjhU F\;le;jhNd 
 
                      - A+fp Kdp itj;jpa rpe;jhkzp 800 nra;As; 513   
  
 Characterized by skin lesions covered with silvery white scales, erythema, itching, 
burning sensation, and thickening of ears, cheeks and nose 
KAALANJAGA PADAI 
 Synonyms: Venparusedhil, sedhiludhirnoi 
Definition 
              According to the definition siddha maruthuvam sirappu, kalanjaga padai is a 
chronic non-infectious, recurrent, inflammatory disorder of the skin characterized by 
reddish, slightly elevated patches covered with silvery white scales. In Siddha system, Skin 
disorders are brought under the clinical entity ―kuttam”. 
Aetiological Factors 
 Unknown aetiology 
 Genetic cause  
Triggering Factors 
 Tonsillitis 
 Respiratory disorders 
 Allergic disorders 
 Stress and strain 
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 Anxiety, depression 
 Seasonal variations 
 Certain drugs(eg) Thambira chenduram 
Clinical Features 
 The lesions are patches and macules which are red in colour with raised margin and 
the lesions are covered by silvery, white and rough and thick scales. 
 The patches are coin shaped. In some, the shape may be either round or oval. 
 There are variations in the size and shape of patches according the site. 
 The skin lesions occur all over body, commonly knee and back of the elbows 
affected. 
 Excessive scaling and generalized erythema develops all over the body. 
 In children this lesion may resemble water drops and this may occur in scalp and 
face. 
 Mild oozing will be present if flexural region(axilla, groin & infra mammary 
regions) are involved in females. 
 One fourth of patients have nail involvement like pitting and dimpling in nature. 
 7% of patients develop affection of joints as psoriatic arthropathy. 
 Prevalence of kaalanjaga padai 
 2% of population are affected by psoriasis 
 5-12 years is the commonest age group 
 Remission and relapses occur 
 Females are commonly affected them males 
Pathology of kaalanjaga padai 
 The kaalanjaga padai  affects the skin and mucous membrane 
MUKKUTTRA VERUPADUGAL ((PATHOGENESIS):           
 Uyir thathukkal 
 Udal thathukkal 
 Kalamarupadu (seasonal changes) 
 Thinai (living lands) 
 Udal vanmai 
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UYIR THATHUKKAL 
 Human body is influenced by three Thathus such as Vaatham, Pitham and Kabam. 
They are responsible for normal physiological conditions of the body. In Kaalanjaga padai, 
the following Mukkutram are commonly affected,  
Disease occurs due to the derangement in  
MUKKUTRA IYAL:   
The function of the three uyir thathus 
a) Vali – Kattru + Veli  
b) Azhal – Thee   
c) Iyyam – Neer + Mann  
 
The alteration of three thathu in their reaction to extrinsic or intrinsic factors results 
in disharmony. This altered harmony and balance variation of the three results in disease. 
Their natural ratio (1:1/2:1/4) to each other is discerned by the physician at the wrist and 
each nadi is individually assessed for its strength, speed and regularity. 
Seasonal variations of kaalanjaga padai 
Vaatham 
       The activities of Vatham are increased during the period of Aani (june-july) ,Aadi (july-
augest) 
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Table 3.1 VATHAM: 
The term vatham denotes vayu, dryness, pain and flatulence. Based on functions and 
locations it is classified into ten types. They are tabulated below. 
S.No Vatham General Features Changes in 
Kaalanjaga Padai 
1 Piranan 
(Uyirkkaal) 
Responsible for respiration and it is 
necessary for proper digestion. 
Normal 
2 Abanan (Keel 
nokkukkaal) 
Responsible for all the downward forces 
such as voiding of urine, stools, semen, 
menstrual flow. 
Normal 
3 Viyanan 
(Paravukaal) 
Dwells in the skin and is concerned with 
the sense of touch, extension and flexion 
of the parts of the body and distribution 
of the nutrients to various parts of the 
body. 
Affected (skin 
colour changed into 
white) 
4 Uthanan  
(Melnokkukaal) 
Responsible for all kinds of upward 
motion such as nausea, vomiting etc., 
Normal 
5 Samanan 
(Nadukkaal) 
Start from the umblicial cord, Samanan 
spread out upto the lower limbs and 
responsible for the balance of other four 
vadha and digestion. 
Affected ( It cannot 
control the other 
vayus) 
6 Nagan Helps in opening and closing of eyelids. Normal 
7 Koorman Responsible for vision, lacrimation and 
yawning. 
Normal  
8 Kirugaran Induces appetite, salivation, all 
secretions in the body including nasal 
secretion and sneezing. 
Affected 
9 Thevathaththan Induces and stimulates a person to 
become alert, get anger, to quarrel, to 
sleep etc., 
Normal 
10 Dhananjeyan Resides in the cranium and produces 
bloating of the body after death. This 
leaves from the body after 3 days of 
death, forming a way through the skull. 
Normal 
 
1. Viyanan  -  Erythematous changes in the affected areas of skin  
2. Samanan  -  Due to other vaayu, it is affected  
3. Kirukaran  -  Loss of appetite  
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Table 3.2 PITHAM: 
It is the thermal life force of the body. It is sub divided into five types. They are  
S.No Pitham General Features Changes in 
Kaalanjaga Padai 
1 Anarpitham Peps up the appetite and aids in digestion. Normal 
2 Ranjagapitham Responsible for the colour and contents of 
blood. 
Normal 
3 Saathagapitham Controls the whole body and is held 
responsible for fulfilling a purpose. 
Normal 
4 Pirasagapitham Dwells in the skin and concerned with the 
shine, glow, texture and its complexion.  
Affected (skin colour 
Changed into white) 
5 Alosagapitham Responsible for the perception of vision. Normal 
 
Table 3.3 KABHAM: 
It is responsible for the stream line functions of the body and maintains body‘s 
defence mechanism intact. It is again classified into 5 types. 
S.No Kabham General Features Changes in 
Kaalanjaga Padai 
1 Avalambagam Lies in the respiratory organs, exercises 
authority over other kabhas and control the 
heart and circulatory system. 
Normal 
2 Kilethagam Found in stomach as it seat, moistens the 
food, softens and helps to be digested. 
Normal 
3 Pothagam Responsible for the perception of taste Normal 
4 Tharpagam Presents in the head and is responsible for 
the coolness of the eyes, sometimes may be 
referred to as cerebrospinal fluid. 
Normal 
 
5 
Santhigam Necessary for the lubrication and the free 
movements of joints. 
Normal 
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Table 3.4 UDAL KATTUGAL  
              Our body consists of seven Udalthathukkal. It gives strength and structure to our 
body. In Kaalanjaga padai patients, Saaram, Senneer, KozhuppuandEnbu are commonly 
affected.   
S.No Udal kattugal General Features Changes in 
Kaalanjaga 
Padai 
1 Saaram  (Digestive 
essence) 
Responsible for the growth and development. 
It keeps the individual in good temperament 
and it enriches the body. 
Affected 
2 Senneer (Blood) Responsible for the color of the blood and 
for the intellect, nourishment, strength of the 
body. 
Affected 
3 Oon (Muscle) Gives lookable contour to the body as needed 
for the physical activity. It feed the fat next 
day and gives a sort of plumpness to the 
body. 
Normal  
4 Kozhuppu (Fat) Lubricates the organs to facilitate frictionless 
functions. 
Normal 
5 Enbu (Bones) Supports and protects the vital organs, gives 
the definite structure of the body and 
responsible for the posture and movements 
of the body. 
Normal 
6 Moolai (Bone 
marrow) 
Nourishes the bone marrow and brain which 
is the centre that controls other system of 
body. 
Normal 
7 Sukkilam/Suronitha
m (Sperm/Ova) 
Responsible for reproduction Normal 
 
Saaram :  Dryness, roughness, tiredness   
Senneer :  Erythematous patches present 
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Table 3.5 PARUVAKALAM: 
S.No Perum pozhuthugal Mukkutra marupaadugal 
1 Kaar kaalam 
(Aavani & Purattasi) 
Mid-August to Mid-October 
VATHAM - Vaetrunilai valarchi  
PITHAM – Thannilai valarchi 
 
2 Koothir kaalam 
(Iypasi & Karthigai)  
Mid-October to Mid-December 
VATHAM – Thannilai adaidhal  
PITHAM - Vaetrunilai valarchi  
3 Munpani kaalam 
(Margazhi & Thai)  
Mid-December to Mid-February 
PITHAM – Thannilai adaidhal  
4 Pinpani kaalam 
(Masi & Panguni) 
Mid-February to Mid-June 
KABHAM – Thannilai valarchi 
5 Elavenir kaalam  
(Chithirai & Vaikaasi)  
Mid-April to Mid-June 
KABHAM – Vaetrunilai valarchi  
 
6 Mudhuvenir kaalam  
(Aani & Aadi)  
Mid-June to Mid-August   
VATHAM– Thannilai valarchi 
KABHAM – Thannilai adaidhal 
 
THINAI (LAND): 
 Siddhars classified the lands into five types. They are   
1. Kurunji  – Mountain range  
2. Mullai  – Pastoral area of the forest  
3. Marudham  – The fertile river bed  
4. Neidhal  – The coastal region  
5. Paalai  – Arid desert  
 
 Kabha diseases will occur in Kurinji land. Pitha diseases occur in Mullai land. 
Vadha diseases occur in Neidhal land. Staying in Paalai land is not good to health. 
Marudham land is the fertile area where no disease occurs. So, Marudham land is 
the best one to stay in. 
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 The winter season gives good health to the man, early summer and later rainy gives 
moderate health. Whereas early rainy and later summer are more prone to diseases, 
that‘s why siddhars called it as Aanaga kaalam. 
Table 3.6 RELATION BETWEEN MUKKUTRAM, KAALANGAL AND THINAIGAL:  
Mukkutram                             Paruvakaalam (Seasons)                Thinai 
Thannilai 
valarchi 
(Accumulation) 
Vaetrunilai 
valarchi 
(Aggravation) 
Thannilai 
adaidhal 
(Alleviation) 
VATHAM Mudhuvenil 
kaalam 
Kaar kaalam Koothir kaalam Vatha disease is 
more prevalent in 
Neidhal land. 
PITHAM Kaar kaalam Koothir kaalam Munpani 
kaalam 
Pitha disease is 
more prevalent in 
Mullai land  
 
KABHAM Pinpani kaalam Elavenil kaalam Mudhuvenil 
kaalam 
Kabha disease is 
more prevalent in 
Kurunji land 
 
UDALVANMAI  
 It is classified into 3 types, they are 
 Iyarkai Vanmai   
               Natural immunity of the body by birth 
 Seyarkai Vanmai    
             Improving the health by intake of nutritious food materials and medicines. 
 Kaala Vanmai  
            Development of immunity according to age and the environment. When the 
Udalvanmai is affected there may be possibilities of occurrence of Kaalanjaga padai. 
 
 IYMPORIGAL               
             In Kaalanjaga padai, Mei is affected. Roughness of the skin, white silvery scales is 
seen. Kanmenthriyam  In Kaalanjaga padai,Kai, Kaal affected as there is difficulty in using 
the limbs.     
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 Piniyariyum muraimai  ( Diagnostic Methods ) 
 Piniyariyum muraimai is the method of diagnosing disease. It is based on the 
following principles:  
  Poriyalaridhal 
  Pulanalaridhal 
  Vinaathal  
 Poriyalaridhal and Pulanalaridhal means examining the patient‘s ―Pori‖ and ―Pulan‖ 
with that of physician‘s ―Pori‖ and ―Pulan‖. ―Vinaathal‖ is a method of enquiring about the 
details of the patient‘s problem from his own words or from his parents or attenders who are 
taking care of the patient, when the patient is not able to speak (or) if the patient is a child.  
ENVAGAI THERVUGAL (Eight tools of examination) are: 
           1. ―ehbg;ghprk; ehepwk; nkhoptpop  
       kyk; %j;jpukpit kUj;JtuhAjk;‖. 
2. ―nka;f;Fwp epwe;njhdp tpopehtpU kyk; iff;Fwp‖ 
 - NjiuaH 
 
 3. ―njhFf;fYw;W ml;ltpj guPl;ir jd;id 
   Fyf;fKyWk; gz;bjNu njspthfg; 
    gFf;fwpa ehbia eP gPbj;J ghU 
   gfHfpd;w thHj;ijiag; ghH ehit ghU 
        tFf;fhpa Njfkij njhl;Lg;ghU 
   tskhd rhPuj;jpd; epwf;fj;ijg; ghU 
      rfpf;fupa kyj;ijg;ghH ryj;ijg; ghU 
   rhHe;j tpopjidg;ghHj;J njsptha;f; fhNz‖. 
- mfj;jpaH ty;yhjp 600 
 
 Naadi (Pulse):   
In Kalanjaga padai, the following types of Naadi could be felt.  They were,  
 
a) Vaathapitham 
 b) Vaathakabam  
c) Pithakabam 
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 Sparisam:    
                  In case of Kaalanjaga padai, slightly raised well defined dry erythematous     
macules or plaques, covered with white silvery scales can be noticed in affected areas 
 
 Niram (complexion):  
                  In case of Kaalanjaga padai, white patches with silvery scales could be noticed at 
affected areas. 
 
 Mozhi (voice):    
                 In case of Kaalanjaga padai no abnormalities were observed.  
 
 Vizhi (eye):    
                 In case of Kalanjaga padai, no abnormality was seen in Vizhi. 
 
 Moothiram (urine):   
               Collection of urine for the determination of Neerkkuri and Neikkuri, is an 
important diagnostic method  
 
 Neerkkuri  
               Prior to the day of urine examination the patient is instructed to take a balanced 
diet. The patient should have good sleep. After waking up in the morning, the first urine 
voided is collected in a clear wide mouthed glass container and is subjected to analysis of 
―Neerkkuri‖ within one and a half an hour. In Kalanjaga padai patients, straw coloured 
urine was noticed.   
 
 Neikkuri   
             The collected specimen (Urine) is kept open in a glass dish or china clay container. 
It is to be examined under direct sunlight, without any shaking of the vessel. Then add one 
drop of gingelly oil without disturbing the urinary specimen and the neikkuri was noted in 
direct sunlight and the diagnosis is concluded as  follows,   
 
Character of Vaathaneer 
―muntd ePz;bby; m/Nj thjk;‖ 
             When the oil drop spreads like a snake, it is called ―Vaathaneer‖  
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Character of Pithaneer  
―MopNghw; gutpd m/Nj gpj;jk;‖ 
           When the oil drop spreads like a ring, it is called ―Pithaneer‖ 
 
Character of Kabaneer  
―Kj;njhj;J epw;fpd; nkhoptnjd; fgNk‖ 
           When the oil drop appears like a pearl, it is called ―Kabaneer‖  
 
Character of Thonthaneer   
           Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are the 
characters of Thonthaneer (mixed type). In Kaalanjagapadai, theNeikkuri was Vaathaneer, 
Pithaneer and Kabaneer.  
 
Anubanam 
―mDghdj;jhNy atpo;jk; gypf;Fk; 
,dpjhd Rf;F,Q;rp – gpDKJfhy; 
Nfhkak;ghy;Kiyg;ghy; Nfhnea;Njd; ntw;wpiyePH 
Mkpijah uha;e;J nra;ayhk;‖ 
- Njiuah; ntz;gh 
 
Pathiyam (Dietary Regimen) 
                 In mild conditions of the disease, salt and tamarind can be taken in little 
quantities. When the condition is severe, tamarind should be avoided and salt must be 
consumed after frying. 
 
―gj;jpaj;jpdhNy gyZz;lhFk; kUe;J 
gj;jpaq;fs; Nghdhy;gyd; NghFk; gj;jpaj;jpy; 
gj;jpaNk ntw;wp jUk; gz;bjHf;F Mjypdhy; 
gj;jpaNk cj;jpnad;W ghh;‖ 
- Njiuah; ntz;gh 
 
―ngUFQ; Nrhs kpWq;Fk; ngUq;fk;G 
tuF fhAld; thioAld; fhnahL 
ciunfhs; ghfw; nfspw;WkPd; cz;bby; 
tphpt jha;f;fug; ghDkpFe;jNj‖ 
 
―GspJtH tpQ;Rq; fwpahH G+hpf;Fk; thjk‖; 
                     - gjhHj;j Fz rpe;jhkzp 
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Diet Regimen ( Pathiyam)  
 Fish, crab, prawn are some seafoods should be avoided.  
 Curd, Jaggery, oil, White gram should be avoided.  
 Non vegetarian diet should be avoided.   
 Alcohol beverages should be avoided.  
 Brinjal should be avoided.  
 In severe cases tamarind should be avoided. 
NIRAIVU:                 
          Substances used for neutralizing the three humors are  
  ―xd;wpa thj gpj;j fgkpitAauh tz;zk; 
ed;wW fwpfnsy;yhk; ehSNk rikg;ghuha;e;j; NjhH 
jpd;wpL kpsF kQ;rs; rPuf aHe;j fhak; 
ntd;wp nfhs; Rf; NfhNlyk; nte;jpak; cs;sp NrHj;Nj‖ 
- gjhHj;jFz rpe;jhkzp 
The patients are well motivated. The nature and course of the disease is explained to 
them, Life-style modification advised. Substances advised for Vaatha disease are:  
 ―nrq;fOePH Nfhilj; Njd;kpsF ey;nyz;nza; 
jq;F ngUq;fhaj; jOjhio – vq;nfq;Fk; 
fl;L rpWKj;J nea; Nfhjpy; cSe;jpitfs; 
thl;L kdpyj;ij kjp.‖ 
- gjhHj;jFz rpe;jhkzp 
 
 Honey collected during summer, pepper, gingely oil, asafoetida, castor oil and black 
gram are very useful in Vatha disease.  
 
KAAPPU (Prevention)  
                As per siddha system the aetiology of the diseases are various. The ultimate 
speciality of siddha system is to prevent the diseases.  
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Yogam:  
               Skin is the reflex of mind and so we should treat not only the physical body but 
also treat mind and soul. There by patients are advised to do yogam practice. Asanas like, 
 
 Savasanam (Resting posture) 
 Padhmasanam (Lotus posture)  
 Pranayamam  (Breathing excersise) 
 
    are all beneficial to relieve stress and strain.        
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            MODERN ASPECT OF DISEASE (PSORIASIS)  
History of Psoriasis 
               The Greeks had a word for it—psora, "to itch"—which could qualify as the 
understatement of the centuries. It has been known since ancient times and was originally 
considered a type of leprosy, It is one of the most common human skin diseases. Noted 
physician Galen (133-200 A.D.) identified psoriasis as a skin disease through clinical 
observation and was the first to call it psoriasis. 
World Psoriasis Day 
               Sunday, October 29, is World Psoriasis Day—a day dedicated to the 125 million 
people around the world living with psoriasis.             
ANATOMY OF SKIN:  
 
Fig. 3.1 
The skin is the protective covering of the body; Skin covers the entire surface of the 
human body. The human skin shows wide variations in structure.  
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1. Thick skin found in Scalp, Ear lobes, Palms, Soles. 
2. Thin skin over the rest of the body. . 
 
 The average thickness of the skin is about 1 to 2 mm.  
 In the sole of the foot, palm of the hand and inter scapular region, it is considerably 
thick measuring about 5 mm.  
 Skin is very thinnest in eyelids and penis measuring about 0.5mm only. The skin is 
composed of a  
 
 Superficial epithelial layer – The epidermis.  
 Connective tissue layer – The dermis or Corium.  
 Another Connective tissue layer loose in texture – The hypodermis or 
subcutaneous layer. 
STRUCTURE OF EPIDERMIS:  
The epidermis is formed of nonvascular stratified epithelium. The average thickness 
of the skin is between 0.07 mm to 0.12 mm. Certain parts like the soles of the feet and the 
palms of the hands it is very thick ranging from 0.8mm to1.4mm.  
 Squamous epithelium is 10 to 11 cells thick in the palms and soles.  
 Squamous epithelium is 3 to 4 cells over the eyelids.  
 The nutrition is provided to epidermis by the capillaries of dermis.   
The epidermis is mainly divided into two main systems,  
1. Malpighian system which forms the bulk (Keratinocytes)  
2. Pigmentary system which produce pigment ( Melanocytes)  
   
  In addition of four types of cells. These are   
1. Keratinocytes  
2. Melanocytes  
3. Langherhans cell  
4. Intermittent cells          
                In the epidermis, another unique cell known as Markel cell or Hascheiben or 
Touch cells here found at the base of epidermal ridges, which are in contact with nerve 
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fibers, they are mostly present in palms, soles, nail beds, oral and genital epithelium, and act 
as slow touch receptors.  
LAYERS OF EPIDERMIS:  
          Epidermis layer can be made out microscopically in a section perpendicular to the 
skin surfaces, the following 5 main layers of the epidermis.  
            These are  
1. Stratum germinatum 
 2. Stratum malpighii  
3. Stratum granulosum  
4. Stratum lucidum  
5. Stratum corneum.  
 
1. STRATUM  GERMINATUM: 
 This is the deepest potion of the epidermis and it is composed of columnar cells 
placed perpendicular to the skin surface, it is also known as basal cell layer.  
 The whole of the epidermis germinates from this stratum hence the name ―stratum 
germinatum‖  
 Any trauma to this layer would result in scarring; trauma above the level of this 
layer heals without scarring.  
 Melanoblasts or melanocytes are found in this layer.  
 Stratum germinatum contain granules of pigment called melanin.      
2. STRATUM  SPINOSUM:  
 It is also known as stratum malpighii or the prickle cell layer.  
 It is superficial to the basal cell layer. 
 It is composed of several layers of polyhedral cells connected to each other by 
intercellular   bridges.  
 Desmosomes present in this layer only. 
 Half size desmosomes occur on the under surface on the under surface of the basal 
cells, which play an important part in the anchoring the epidermis and dermis.  
 All keratinocytes adhere together by desmosomes.  
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3. STRATUM  GRANULOSUM:  
 It is superficial to the stratum malpighii  
 It is composed of flat, fusiform cells which are one to three layers thick, the. Cells 
contain irregular granules of keratohyalin and lysosomal enzymes and cystine rich 
proteins.  
 Lamellar granules also known as odland bodies.  
 These odland bodies take part in the waterproof barrier function of the epidermal 
permeability.  
4. STRATUM  LUCIDUM: 
 Superficial to the stratum granulosum.  
 It is pale, wavy looking layer known as stratum iucidum  
 It is made up of many layers of flattend epithelial cells.  
 This layer contains refractile droplets of eleidin. 
 5. STRATUM CORNEUM:  
 This is the most superficial layer, the outer surface of which is exposed to the 
atmosphere. It is also known as horny layer. It is the outer most layer and consists of 
dead cells, which are called as corneocytes.  
 It consists of many layers of non nucleated, flattened, cornified cells  
 It is this layer which becomes thicker with the application of intermittent mechanical 
pressure.  
 This layer is thickest in the palms of the hands and the soles of the feet, but thinnest 
on the outer surface of the lips, on the glans penis and the eyes.  
DENDRITIC CELLS OF EPIDERMIS:  
 These are melanocytes, Langherhans cells, and indeterminate cells.  
 The melanocytes are the pigment producing cells and are derived in foetal life from 
neural crest.  
 The cells of langherhans are found about the middle of epidermis.  
 The junction of epidermis and dermis is formed by basement membrane(Basal 
lamina)  
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DERMIS: (CUTIS VERA OR CORIUM)  
Dermis is profusely supplied with blood vessels, Thickness of dermis is 1 to 3 mm, 
it is made up of dense collagen fibers and fibroblasts. The collagen fibers contain the 
enzyme collagenase which is responsible for wound healing.  
Dermis is made up of 2 layer, these are  
1. Superficial papillary layer  
2. Deeper reticular layer  
 
1. SUPERFICIAL  PAPILLARY  LAYER:  
 The layer projects in to the epidermis, it contain blood vessels, lymphatics and nerve 
fibers  
 Dermal papillae are finger like projections arising from the superficial papillary 
dermis. 
 2. DEEPER RETICULAR LAYER:  
 It is made up of reticular and elastic fibers. 
 It is found around the hair, sweat glands and sebaceous glands.  
 It also contain mast cells, Nerve ending, lymphatics and fibroblasts.   
APPENDAGES OF THE SKIN:  
    The appendages of the skin are five These are,  
1. Sweat gland 
 2. Sebaceous gland  
3. Hair  
4. Arrectorpili muscle  
5. Nails.   
1. SWEAT GLAND:  
These are 2 types  
 Eccrine gland.  
 Apocrine gland.   
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ECCRINE GLAND:  
 They are the ordinary, small sized 0.3 mm to 0.4 mm.  
 Sweat glands are distributed all over the skin except on the beds of nail, margins of 
lips and the glans penis  
 Over 3 million sweat gland are  present at birth.     
 APOCRINE GLAND:   
 Glandular portion is very large and may measure 3 mm to 5 mm in diameter. 
 They occur in the axilla, areola and nipples of breasts, umbilicus, around the anus 
and the genitalia. 
 They are specialized sweat glands, and their secretion is odoriferous with a 
secondary sexual significance.  
2. SEBACEOUS GLAND:  
 They are scattered all over the integument in association with the hair follicles. 
 They are absent in the hairless portions of the body like the palms of the hands, the 
soles of the feet.  
 The ducts of the sebaceous glands are lined by stratified squamous epithelium which 
is continuous with the external sheath of the hair, and with the malpighian layer of 
epidermis.  
3. HAIR:  
 Hair is found on almost every part of the body surface except on the palms, soles, 
the dorsal surface of the terminal phalanges, the inner surface of the labia, the inner 
surface of the prepuce and the glans penis.  
 Hairs differ in length, thickness and colour in different parts of the body and in 
different races. 
 There are three types of hair, long, short, thick bristles.  
 Hair grows about 1-2 cm per month.  
 Hair follicle and its hair can be anatomically divided in to 3 segments  
 Infundibulam 
 Isthumus  
 Inferior.  
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4. ARRECTOR PILI:  
 Arrectorpili muscles are the small bundles of plain muscles fibers, which is extend 
from the connective tissue sheath of the hair follicles to the epidermodermal 
junction. 
 When these contract under the effect of cold or emotions. This move the hair into a 
more vertical portion is called appearance of ‖ghoose flesh‖  
5. NAILS:  
 These are semi transparent, plate like horny structure, covering the dorsal surfaces of 
the distal phalanges of the fingers and toes. 
 Nail parts are 
 Root  
 Nail plate  
 Nail bed 
 Lunula  
 Lateral and posterior nail fold  
BLOOD VESSELS OF SKIN:  
 The blood supply of the skin originates from the large number of arteries 
forming anastomosis in the deepest part of the dermis. From the single vessels 
run upwards and form a second network in the upper dermis.  
 Finally terminal arterioles ascend in to the papillae ending in capillary loops, 
which drain into connective venules.  
 The blood is returned to the large veins in the subcutaneous tissues.  
LYMPHATICS OF THE SKIN:       
 The skin contains a rich network of lymphatics which drains in to a larger vessel 
in the hypodermis.   
NERVE SUPPLY OF SKIN:  
 The nerve supply of the skin consists of a motor sympathetic portion derived 
from the sympathetic ganglia.  
 Sensory spinal portion arising from the dorsal root ganglia.  
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PHYSIOLOGY OF SKIN:  
The skin performs a multiple of functions, though the primary function of skin is the 
protection of organs, it has many other important functions.  
These are :  
1. Protective function.  
2. Sensory function.  
3. Storage function.  
4. Synthetic function.  
5. Regulation of body temperature.  
6. Regulation of water and electrolyte balance.  
7. Excretory function.  
8. Absorptive function.  
9. Secretory function.  
10. Gaseous exchange.   
 
1. PROTECTIVE FUNCTION:                    
Skin forms the covering of all organs of the body and protects these organs from the     
following factors:      
i. Bacteria and toxic substances 
 ii. Mechanical flow 
 iii. Ultraviolet rays.  
 
2. SENSORY FUNCTION:  
Skin is considered as the largest sense organs in the body. It has many nerve 
endings, which form the specialized cutaneous receptors. These receptors are stimulated by 
the sensations of touch, pain, pressure or temperature sensation and convey these sensations 
to the brain via afferent nerves.     
3. STORAGE FUNCTION: 
Skin stores fat, waters, chlorides and sugar. It can also store blood by the dilatation 
of the cutaneous blood vessels.       
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4. SYNTHETIC FUNCTION:   
            Vitamin D3 is synthesized in skin by the action of ultraviolet rays on cholesterol.  
 
5. REGULATION OF BODY TEMPERATURE:  
             Skin plays an important role in the regulation of body temperature. Excess heat is 
lost from body through skin by radiation, conduction and evaporation. ‗ 
 
6. REGULATION OF WATER AND ELECTROLYTE BALANCE:   
          Skin regulates water balance and electrolyte balance by excreting water and salts 
through sweat. 
 
 7. EXCRETORY FUNCTION: 
Skin can excrete small quantities of waste materials like urea, salts and fatty 
substances.  
8. ABSORPTIVE FUNCTION:             
Skin can absorb the fat soluble substances and some ointments.  
9. SECRETORY FUNCTION:  
Skin regulates sweat through sweat glands and sebum through sebaceous glands. 
Sebum keeps the skin smooth and moist.   
10. GASEOUS EXCHANGE: 
           A small amount of gaseous exchange through the skin.  
EMBRYOLOGY OF THE SKIN:  
              The whole of the skin epidermis and dermis is a unified integrated organ system, 
but it develops from two different primitive embryonic layers epidermis from the ectoderm 
and dermis from the mesoderm.  
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PSORIASIS  
DEFINITION:   
          It is a common chronic and non-infectious skin disorder, characterized by dry 
erythematous plaques, well defined slightly raised covered by a white silvery scales typical 
in extensor distribution ,it affects all over the body.  
EPIDEMIOLOGY:  
1. PREVALANCE:  
 It is distribution in world wide. 
 Fairly common in the tropical countries.  
 It is pandemic in temperate climate.   
 Attacks are more common in winter than summer. 
 Natural tendency to clear up with the warm weather. 
 A fair number of attacks develop in the monsoon. 
 It affects 0.6%-4.8% of people worldwide. 
 150,000-260,000 new cases of psoriasis are diagnosed each year. 
 About 400 people die from complications caused by psoriasis every year.  
 About 11% patients have psoriatic arthritis.  
 Plaque type is most common in 80% of psoriasis patients.       
2. AGE OF ONSET:  
 First peak of onset between 4-16 yrs.   
 Early onset family history present. 
 Late onset family history is not present.  
3. SEX: 
 Men and women are equally affected.  
4. SEASON:  
 Most patients worse in winters. 
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AETIOLOGY:   
1. The exact cause is unknown - Autoimmune Disease  
2. Stress.  
3. Disturbed fat metabolism.  
4. Hormonal imbalance.  
5. Septic focus.  
6. Allergy.  
7. Anxiety states. 
 8. Lowered response of the cyclic AMP system to prostaglandin E1 in epidermis.  
9. Mental trauma.  
10. Fever.  
11. Digestive upsets. 
 12. Physical injury:  
 Scratches.  
 Surgical incisions and injuries. 
 13.  Infection: 
 β - Hemolytic streptococcal infection- precipitates guttate lesions.  
  HIV infection-Explosive psoriasis.  
14. Herido familial and Genetic factors: 
 Increased in familial cases.  
 Greater concordance in monozygotic twins (70%)  
 Dizygotic twins (30%)  
 Increased association of HLA- CW6 20 times increased risk with early 
onset of psoriasis.  
PRECIPITATING FACTORS:  
 Diabetic‘s mellitus.  
 Psychological stress.  
 Hot water bathing  
 Skin dryness.  
 Obesity. 
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 Local Pressure.  
 HIV  
 Trauma. 
 Purines in the diet.  
 Identical twins.  
 Immune system reacting to skin cells.  
 Microbes. 
Staphylococcal aureus 
Candida albicans.  
 Drugs:  
Anti malarial drugs.  
Lithium.  
 Beta adrenergic blockers drugs.  
 NSAID drugs.  
 Corticosteroid withdrawal may aggravate psoriasis.(Pustular psoriasis)    
 
Natural History of the Disease and Triggers: 
 
The goal of control versus cure is a more practical outcome of treatment. Many 
randomized controlled clinical trials involving children under the age of 12 years have 
reported on two topical treatments: calcipotriol and corticosteroids. Avoidance of triggers 
like trauma (Koebner phenomenon), including physical, surgical, or inflammatory trauma, 
should be borne in mind in this age group. A strong association between pharyngitis by 
group A beta-hemolytic streptococci and the clinical activity of psoriasis (guttate psoriasis) 
is now well established and should be properly investigated where relevant.  
Poriasis in paediatric Population 
 Although pediatric psoriasis is not uncommon, there are limited epidemiological 
data available to date.Prevalence rates vary according to the following: age, sex, 
geographical location. One-third of patients develop psoriasis in childhood, and the 
incidence of childhood psoriasis increases with age. In children it exhibits  more pruritic, 
common in girls, and the lesions are relatively thinner, softer, and less scaly.  
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Scalp Psoriasis 
 Often, the first place for these patches to occur in children is on the scalp. 
 Facial involvement in children is a frequent observation in majority of the reports, 
which varies from 18 to 46%, whereas mucosal involvement has been rare in Indian 
children.  
 
Guttate Psoriasis 
 Another common type of psoriasis to affect children is called guttate psoriasis. 
 This type is associated with several small, raindrop-like patches forming in large 
groups. When guttate psoriasis occurs in children and young teenagers, it is often 
the result of a secondary infection in the throat, such as strep throat. 
 Other upper respiratory infections are also common triggers for psoriasis to start. 
Though not always the case, guttate psoriasis may go away within a few months and 
not return. 
Flexural Psoriasis 
            Children will often develop flexural psoriasis. This term refers to the large, red 
patches of psoriasis that occurs around folds in the skin, such as at the joints. 
 
Plaque Type Psoriasis 
           Plaque type is the most common form of disease, but certain clinical variants are rare 
in children like erythroderma, arthropathy, and localized and generalized pustular psoriasis.   
 
Palmoplantar type Psoriasis 
          Palmoplantar psoriasis comprises approximately 4% of all psoriasis in 
children.  Presentation varies from thick scaling with fissuring to a glazed erythema.This 
type of psoriasis is very common among Indian children which can be explained by the 
practices of walking barefoot and increased incidence of injuries. 
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PATHOGENESIS OF PSORIASIS: 
Psoriasis appears to be largely a disorder of keratinization 
↓ 
The basic defect is rapid replacement of epidermis in psoriatic lesion. 
3 to 4days instead of 28 days in normal skin. 
↓ 
There are marked vascular changes in upper dermis 
 
Recently the presence of abnormal neural cells has been demonstrated in Psoriatic plaques.  
 
Fig. 3.2 
 PATHOGENESIS OF PSORIASIS  
 Psoriasis was long considered either a disorder of keratinocytes growth or a 
chronic inflammation.  
 Advancement in immunologic techniques and in genetic analyses has 
resulted in a reappraisal of the pathophysiology involved.  
 Psoriasis consider as an organ specific autoimmune disease that is triggered 
by an activated cellular immune system and it similar to other immune 
mediated disease.  
 The definition of autoimmune disease as ― a clinical syndrome caused by the 
activation of T cells and Bcells, or both, in the absence of an ongoing 
infection or other discernable cause‖  
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 Pathogenesis of psoriasis still poses a challenge to the scientific community 
to once and for all, establish how and why it occurs and consequently to 
develop the magic drug to treat it.    
 Psoriasis is an immunological disease, characterized by interplay of  
I. Immunological factors.  
II. Cellular components. 
III. Signaling molecules.  
IV. Biochemical changes.  
V. Histological changes.   
 
These  plays major role in pathogenesis.  
 
I. IMMUNOLOGICAL FACTORS IN PSORIASIS:   
Both innate or acquired immune changes are though to be responsible  
for the  Development of psoriatic plaques 
↓ 
Different types of helper T subsets, dendritic cells, plasmacytoid dendritic  
cells as well as Langherhans cells have been found to play a role in psoriasis. 
↓ 
T cells plays important role in psoriasis 
↓ 
Autoimmunity as a major factor in pathogenesis. 
↓ 
The presence of T cells in the inflammatory infiltrate in psoriatic plaque  
obviously indicates the immune mediated or an autoimmune basis for the  
Pathogenesis of psoriasis. 
 
II. CELLULAR COMPONENTS IN PATHOGENESIS OF PSORIASIS:    
        Cellular components are :  
a) T cells  
b) Keratinocytes  
c) Langherhans  
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Fig. 3.3 
CELLULAR COMPONENTS OF PSORIASIS   
A. T CELLS:  
 T cells play a key role, with the epidermal T cells being CD8+ & Dermal 
cells being CD4+.  
 These cells include memory T cells, natural killer cells T cells& Th17& 
Th22. 
 Th17& Th22 cells which are subsets of CD4+ cells are now considered 
important in pathogenesis of the psoriatic plaque.  
 They are stimulated by IL-23 & respectively produce IL-17& IL-22 which 
mediate dermal inflammation and epidermal hyperplasia.    
  B. KERATINOCYTES: 
 Keratinocytes cells express transcription factor STAT- 3, which may be 
pathogenic.  
C. LANGERHANS CELLS: 
 Langherhans cells secrete cytokines, which are mitogenic and chemotatic. 
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 III. SIGNALLING MOLECULES IN PATHOGENESIS OF PSORIASIS: 
 Include cytokines growth factors like interleukins, Chemokines, Interferon‟ s and 
their respective receptors. 
 Characterized by up regulation of Th1 cytokines and reduction of anti inflammatory 
cytokines IL-10.  
 Other important molecules include TNF-α, IL-15, IL-17, IL-22 and IL-23 
 IV. BIOCHEMICAL CHANGES IN PATHOGENESIS OF PSORIASIS:  
 Cyclic nucleotide increased levels in cGMP or decreased levels of cAMP.  
 Arachidonic acid level is increased and it metabolites are also increased 
 Polyamines are also increased in levels.  
 PROTEINASE: increased in levels of plasminogen activator and their inhibitors.  
 Calmodulin is also increased in levels.  
   V. HISTOLOGICAL  CHANGES IN PATHOGENESIS OF PSORIASIS:  
 Epidermal changes increass epidermal proliferation in two ways  
 One is increased growth fraction from normal of 30 to 100% in psoriasis.  
 2nd is shortened epidermal turn over time from normal of 60 to10 days in psoriasis. 
 Important changes seen in dermal layer. 
 Include dilated and tortuous capillary loops and proliferation of fibroblasts.        
MOST COMMON SITES:  
1. AREAS COMMONLY AFFECTED:  
 Scalp 
 Back of elbows  
 Front of knees and legs 
 Lower part of the back of the trunk 
 Sole 
 Palm 
 2. MAY ALSO BE AFFECTED:  
 Nail 
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  3. RARELY AFFECTED:  
 Mucus membrane  
CLINICAL FEATURS OF PSORIASIS:    
 Typical distribution is extensor 
 Lesions are bilaterally symmetrical  
 Typical coin shaped lesion 
 Big plaques of the size of palm of the hand  
 The lesions are slightly raised above the surface of skin 
 Absence of itching 
 But itching present in tropical countries 
 Slight or moderate purities present  
 Secondary psychogenic stress present  
 Secondary lichenification present  
 Scalp is involved almost all cases 
 No matting of hair  
 Nail is also involved with 3types of lesion 
                         I. Pitting  
II. Seperation of nail from the nail bed and walls  
III. Thickening of the nail and collection of hyperkeratotic debris under the 
nail.  
 The palms of the hands and soles of the feet also involved in patches of 
hyperkeratosis and fissures on erythematous bases.  
IMPORTANT SIGNS OF PSORIASIS:  
 1. Candle greeze sign.  
2. Auspitz sign.  
3. Koebner‘s phenomenon.   
1. CANDLE GREEZE SIGN( Tache de bouge) :  
          Psoriatic lesion is scratched with the point of a dissecting forceps a candle greeze like 
scale can be repeatedly produced even from the non scaling lesions this is called candle 
greeze sign (Tache de bouge).   
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2. AUSPITZ  SIGN:  
         The complete removal of scale produces pin point bleeding.   
3.KOBNER’S PHENOMENON:  
Psoriatic lesions may develop along the scratch lines in the active phase this is called 
Koebner‘s phenomenon.  
SITES OF PREDILECATION OF PSORIASIS:      
 Lesions are usually bilaterally Symmetrical. 
 Favours pressure points at extensor surface of                                 
 Elbows                                 
 Knee                                   
 Scalp                                  
 Fore head                                  
 Nape of neck                                  
 Trunk                                  
 Buttocks                                   
 Lumbosacral region                                                                                  
 Periumblical area                                     
 Palms and soles.  
 Usually with lesions at other sites, but sometimes in isolation. 
 Infrequent involvement of photo exposed sites, involvement of face uncommon and 
indicates refractory psoriasis 
 Intertriginous involvement in flexural psoria  
CLINICAL TYPES OF PSORIASIS:  
CLASSIFICATION:  
Psoriasis is classified based on its onset, evolution and morphology into     
1. Chronic plaque psoriasis (psoriasis vulgaris)  
2. Acute guttate psoriasis  
3. Pustular  psoriasis 
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1.CHRONIC PLAQUE PSORIASIS:  
There are several variants of chronic plaque psoriasis  
 
A) MORPHOLOGICAL VARIANTS:  
a) Small plaque psoriasis 
 b) Rupioid psoriasis  
c) Para psoriasis  
 
B) VARIATION OF MORPHOLOGY DUE TO SITE:  
a) Flexural psoriasis  
b) Annular psoriasis  
c) Scalp psoriasis (Corona psoriatica)  
d) Penile psoriasis 
 e) Psoriasis of palms and soles (psoriasis inverses)  
  
ASSOCIATIONS OF PSORIASIS:  
In a patient with chronic psoriasis, always check for nails and joint involvement.  
a) Psoriatic nails  
b) Musculoskeletal system(Psoriasis arthopathica) 
 c) Metabolic syndrome.   
1. CHRONIC PLAQUE PSORIASIS(CPP):              
Chronic plaque psoriasis is the commonest form of psoriasis       
 MORPHOLOGY:  
                 The prototype lesion of CPP is a mildly itchy papule which is  
 Well demarcated 
 Erythematous - Deep pink to red  
 White silvery scales, but is profuse adherent in elephantine  
  Indurated and raised.  
  Size and number of lesions variable  
  Koebner‟ s phenomenon +ve  
  Auspitz sign +ve   
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A) MORPHOLOGICAL VARIANTS:  
a) SMALL PLAQUE PSORIASIS (SPP):  
  Smaller 1- 2cm lesions  
  Resemble like guttate psoriasis  
  SPP occurs in older patients  
 It is scalier and has a more chronic course.   
b) RUPINOID PSORIASIS:  
  Lesions with heaped up scales so appear conical 
  Scales are firmly adherent to the underlying skin look like  
  Lesions are classically present in Reactive arthritis(Reiter‟ s syndrome)  
  Characterized by HLA B27 +ve, Antecedent infection, Arthritis, Conjunctivitis, 
Keratodermablennorrhagicum.   
c) PARAPSORIASIS:  
 Para psoriasis is a group of rather infrequent, idiopathic and asymptomatic 
erythrodermic or scaly papule dermatoses.  
 It is a non specific reaction pattern of the skin which may represent an intermediary 
stage of psoriasis.   
B) VARIATION OF MORPHOLOGY DUE TO SITE:  
 a) FLEXURAL PSORIASIS: 
 Commonly occurs in elderly females, because lesions are present in moist friction 
prone areas.  
 Lesions are well defined and erythematous (Salmon pink)  
 Occurs in flexur like the axilla, inframammary folds, vulva and gluteal cleft.   
b) ANNULAR PSORIASIS:  
 The central clearing of the circular lesions produces ringed lesion.  
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c) SCALP PSORIASIS:  
 Lesions may occur along the scalp border is called corona psoriatica.  
 Sharply defined, indurated, scaly plaques present.  
 Scaling looks like Asbestos, especially on the occipit.  
d) PENILE PSORIASIS: 
 In uncircumcised males, scaling is absent on glans but lesions  continue                            
to be erythematous and well defined.  
 In circumcised patients, the lesions on the glans are similar to  psoriatic lesions.  
e) PSORIASIS OF PALMS AND SOLES:                 
 Lesions are bilaterally symmetrical (Psoriasis inversus)  
 Lesions are well defined, Symmentrical, erythematous, thick  plaques with white 
silvery scales may be profuse or minimal.  
2. ACUTE GUTTATE PSORIASIS:  
 Occurs in children and adolescents  
 May be precipitated by streptococcal tonsillitis 
 Lesions appear in several crops of small, erythematous papules  withminimal scaling  
 Side of predilection is trunk. 
 3. PUSTULAR PSORIASIS:  
 It occurs mostly in withdrawal of topical or systemic steroids 
LOCALIZED:  
Inchronicplaque psoriasis, when plaques are  surrounded with pustules 
 Pustules and crusts are seen on distal part of fingers and in nail  bed  
GENERALISED:  
 Is a serious condition 
 Constitutional symptoms like high fever, chills and tachypnea  seen 
 Is characterized by generalized fiery red Erythema followed by appearance of waves 
of tiny. 
 Appearances of new pustules as the old ones are crusting.  
47 
 
ASSOCIATION OF PSORIASIS:  
NAIL PSORIASIS:   
 Nail changes due to                      
 Nail matrix psoriasis                    
 Nail bed psoriasis  
 Nail matrix psoriasis: Manifests as pitting  
 Nail bed psoriasis: Nail plate thickening, subungual hyperkeratosis, discoloration 
and dystrophy of nail plate, oncholysisand oil spots are specific for psoriasis.  
A. MUSCULOSKELETAL SYSTEM (PSORIASIS ARTHOPATHICA): 
 Dactylitis and enthesitis is typically seen there are also seen 5 clinical 
patterns  
 seen these are  
 Asymmentrical oligoarthritis         
 Symmetrical rheumatoid arthritis                                        
 Distal interphalangeal arthritis         
 Arthritis mutilans        
 Axial arthritis  
B. METABOLIC SYNDROME: 
 In patients with psoriasis, there is an increased prevalence of 
 Hypertension  
 Diabetes mellitus (Insulin resistance)  
 Obesity 
 Dyslipidemia 
 Coronary artery disease  
COMPLICATIONS   
            Complications of psoriasis may include the following: Secondary infections, 
Psoriatic arthritis, possible increased risk of lymphoma, cardiovascular disease, ischemic 
heart disease, and Mitral valve prolapse. Among these, Psoriatic arthritis is a major 
complication.        
                                             (Ref: ard.bmj.com › Volume 64, Issue suppl2)      
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SEVERITY OF PSORIASIS: 
 A PASI score is a tool used to measure the severity and extent of psoriasis (Psoriasis 
area and severity index), it takes few minutes and experience to calculate it 
accurately.  
 A representative area of psoriasis is selected for each body region. The intensity of 
redness, thickness, scaling of the psoriasis is assessed as none(0) , mild(1), 
moderate(2), severe(3), very severe(4). 
 The percentage area affected by psoriasis is evaluated in the four regions of the 
body. In each region the area expressed as nil(0), 1-9%(1), 13-29(2), 30-49%(3), 50-
69%(4), 70-89%(5), 90-100%(6). 
 Head and neck, upper limbs, trunk, lower limbs calculations for area, each of the 
body area scores is multiplied by the area affected.       
DIFFERENTIAL DIAGNOSIS  
Nummular eczema  
Rounded, circular desquamative erythematous lesions covered with vesicles, crusts, 
and scales, very itchy. Patients have whether atopic or allergic diathesis. Epicutaneous 
allergy tests are frequently positive.  
Pityriasis rubra pilaris    
In typical cases follicular papules and infiltrating scales are observed as well as 
typical hyperkeratosis.  
Lichen simplex chronic  
This disease shows dry and itchy oval plaques and resembles psoriasis as a shape but 
not have silvery scales Auspitz and candle signs  and shows violaceous tint.  
Pityriasis alba   
It shows a white plaque, like psoriasis but have not an erythema. It has been seen 
only face.  Psoriasis usually affects more than one area of the body. Red skin covered with 
greasy-looking white or yellowish scales.  
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RULE OUT OTHER TEST FOR PSORIASIS:  
 Metabolic syndrome, diabetes, hypertension and dyslipidemia  
 Hypocalcaemia especially in pustular psoriasis  
 Anaemia and hypoproteinemia in erythrodermic psoriasis.  
DIAGNOSIS OF PSORIASIS   
          There are no laboratory tests which will positively identify psoriasis. The blood 
count, Urine analysis, ESR and other hematologic chemical and serologic studies are within 
normal limits in most cases of psoriasis.  
The diagnosis of psoriasis is based upon:  
1. The family history of psoriasis  
2. The typical distribution of the lesions on the scalp, elbows, knees, the front of 
the legs, back and nails  
3. Well-defined non-indurated dry erythematous areas with silvery layer-
uponlayer scaling 
4. The candle – grease sign (when a psoriatic lesion is scratched with the point 
of a dissecting forceps, a candle-grease-like scale can be repeatedly produced 
even from the non-scaling lesions. This is CG sign)  
5. Auspitz sign (Complete removal of a scale produces pin-point bleeding)  
6. Koebner‘s phenomenon (Psoriatic lesions may develop along the scratch lines 
in the active phase) 
7. Little or no itching  
8. History of previous attacks and seasonal variations of the disease.       
DIET FOR PSORIASIS PATIENTS:  
TO TAKE: 
                       1. All green leafy vegetables.  
2. Low consumption of animal fats and the quantity of food.  
3. High protein diet  
4. Salmon Fish  
5. Carrot 
 6. Tomatoes  
7. Grains.  
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TO AVOID:  
1. Oil foods.  
2. High fat diet  
3. Alcohol 
 4. Junk foods  
5. Red meat  
6. Dairy products  
7. Night shade vegetables 
 8. Citrus fruits  
9. Gluten protein in diet  
10. Condiments.       
 
PROGNOSIS:  
 A permanent cure is not yet known  
 Individual attacks can, almost always controlled satisfactorly 
 Disease is non infectious  
 The disease does not leave scar  
 Flexural, erythrodermic and pustular psoriasis take longer to heal than the typical 
variety 
 The palmar and nail lesions are rather resistant to treatment.  
 Patient suffer from the disease on and off throughout their lives. 
 Complications in psoriasis are infrequent.   
MANAGEMENT:  
 The general health of the patient should be maintained. 
 The patient‘s life should be regulated so that no undue stress affects either body (or) 
mind.  
 A moderate, warm climate, frequent sunbaths before the onset of the winter, and 
visits to sulphur springs, all of which are useful in bringing down the relapse rate.    
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DRUG REVIEW 
1.mKf;fuh #uzk;: 
    fz;blh aKf;fuh #uzj;ijf; 
        fUfNt gyk;gj;J epWj;Jf;nfhz;L 
    tz;blha; tbnfhz;L #uzNknra;J 
         thy;kpsF FNuhrhzp gwq;fpg;gl;il 
    fz;blha; fUQ;rPu fk;fLf;fha;Rf;F 
         fLFNuh fzpthY Oitauj;ijjpg;gpyp 
    ,z;blha; tiftiff;Fg; gyNkJ}f;F 
         ,bj;jid Kd;kUe;jpw; rksha;NrNu. 
    rkdhfr; rPdpnahU ehyPnyhd;W 
         rhhpj;J ntUfbjhd; me;jpre;jp 
    mkdhf Mtpd;nea; Nrh;j;Jf;nfhs;S 
         miuahg;G Nkfntb fpue;jpF\;lk; 
    vkdhd thAnthL fbtp\q;fnsy;yhk; 
         vypfbAk; rpytp\q;fs; G+uhd;nra;ahd; 
    fkdhd NkfnkhL thAgpj;jk; 
         fod;WNghk; gj;jpae;jhd; fz;Lnfhs;Ns. 
- gpuk;kKdp fUf;fil #j;jpuk; 380 
 
1. mKf;fuh (Withania somnifera .Linn) 
Other Regional Names: 
 
Eng :  Winter cherry 
Ma l:  Amukkuram 
Tel :  Penneru-gadda 
 
Rit   -  (ahTk;) ifg;G  
tPhpak;  - ntg;gk; 
gphpT   - fhh;g;G 
 
nra;if: 
tPf;fKUf;fp 
cwf;fKz;lhf;fp 
clw;Nww;wp 
cly;ntg;gfw;wp 
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nghJFzk;: 
nfhQ;re; Jth;g;ghq; nfhbafak; #iyahp 
kpQ;Rfug; ghd;ghz;L ntg;gjg;G–tpQ;rp 
KRTW NjhlKk; Nkhfk;md Yz;lhk; 
mRtfe; jpf;nfd; wwp. 
- mfj;jpaH Fzthflk; 
Taxonomical classification 
Kingdom           -  Plantae 
Subkingdom     -  Tracheobionta 
Division             -  Angiosperma 
Class                -  Dicotyledons 
Order                - Tubiflorae 
Family              -  Solanaceae 
Genus               -  Withania 
Species             -  somnifera 
  
Botanical description: 
             This species is a short, tender perennial shrub growing 35–75 cm (14–30 in) 
tall. Tomentose branches extend radially from a central stem. Leaves are dull green, elliptic, 
usually up to 10–12 cm (4 to 5 in) long. The flowers are small, green and bell-shaped. The 
ripe fruit is orange-red.  
Chemical constituents 
 Alkaloids  
               Anaferine 
   Scopoletin 
   Somniferinine 
 
 Steroidal lactones.  
                        Tropine and Cuscohygrine.  
                        withanolides 
                        withaferin A 
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Pharmacological activity: 
 
 Anti-inflammatory activity 
 Immunomodulatory activity, 
 Anti-stress/Adaptogenic Activity 
 Antitumour Activity 
 
2.gwq;fpg;gl;il (Smilax china.Linn): 
Other regional names: 
Eng :  China root 
Mal :  Pavu 
Tel :  Piranki- chekka 
 
Rit : ,dpg;G 
jd;ik : jl;gk; 
gphpT : ,dpg;G 
 
nra;if:  
clw;Nww;wp 
Nkfg;gpzptpyf;fp 
fhkk; ngUf;fp 
J}a;ikahf;fp 
 
nghJFzk;: 
“jhfk; gythj jhJel;lk; Gz;gpsit 
 Nkfq; fpue;jp tPo;%yf; - NjfKld; 
      Fl;il gfe;jNkw; nfhs;tkdk; Nghk;gwq;fpg; 
      gl;ilapid Ar;rhpj;Jg; ghh;”           
-NjiuaH Fzthflk; 
 
Taxonomical classification: 
Kingdom       -  Plantae 
Clade            -  Angiosperms 
Clade            -   Monocots 
Oredr            -  Liliales 
Family          -  Smilacaceae 
Genus           -  Smilax 
Species         -  china 
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Botanical description 
                  Smilax china is a hard tendril climbing vine with sparsely prickled or unarmed 
stems and thick tuberous rhizomes. The petiole is 0.5-1.5 cm, narrowly winged for half to 
one third of its length. Leaves simple, alternate, elliptic and rounded at base, prominently 
nerved and measures 3-10 cm x 1.5-6 cm. The inflorescence is born in axil of young leaf, of 
one umbel of both sexes which 10-25 flowered, representing subglobose and base 
subglobose measuring 2-3 mm in diameter with many small bracteoles. The male flowers 
have sepals of yellowish green and measuring 3.5-4.5 x 1.5-2.5 mm. The stamens measure 
3-4 mm. The filaments are filiform in shape. The female flowers have six staminodes. The 
fruits which are red berries measures 0.6-1.5 cm in diameter and minutely white powdery. 
Chemical constituents: 
                Root contains fat, sugar, glucoside, colouring matter, saponin (Sarasasapogenin) 
gum and starch. 
 
Pharmacological activity 
                Anti inflammatory, 
                Antioxidant 
                Antipsoriatic 
 
3.thy;kpsF (Piper cubeba.Linn ) 
Other regional names: 
Eng  :  Tail - pepper 
Mal  :  Val - milaka 
Tel  :  Tokamiriyalu  
 
Rit  : fhHg;G , tpWtpWg;G 
jd;ik : ntg;gk; 
gphpT  : fhHg;G 
 
 
nra;if:  
Nfhioaw;wp 
ntg;gKz;lhf;fp 
mfl;Lthafw;wp 
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nghJFzk;: 
thjgpj;j Iak; tapw;W typjhfQ; 
rPjk; gyNeha; rpijAq;fhz; - Nghj 
mjpjP gdkhk; mzq;fuNr! ehSe; 
Jjpthy; kpsfUe;j nrhy;. 
   -mfj;jpaH Fzthflk; 
 
Taxonomical classification 
Kingdom         -  Plantae  
Subkingdom     - Tracheobionta        
Division             -  Magnoliophyta   
Class                  -  Dicotyledons   
Subclass            -  Piperales  
Family               -  Piperaceae  
Genus    -  Piper  
Species             -  cubeba  
Botanical description 
               This is a perennial plant, with a climbing stem, round branches, about as thick as a            
goose-quill, ash-colored, and rooting at the joints.  The leaves are from four to six and a half 
inches long by one and a half to two inches broad, ovate-oblong, acuminate, and very 
smooth.  Flowers arranged in spikes at the end of the branches; fruit, a berry rather longer 
than that of black pepper. 
Chemical constituents: 
 Essential oil  
 Piperin 
 Monoterpenes (sabinene 50%, carene, α-thujene, 1,4-cineol and 1,8-cineol) 
and sesquiterpenes (copaene, α- and β-cubebene, δ-cadinene, caryophyllene, 
germacrene, cubebol). 
 Lignanecubebin (2%) 
 Hinokinin, clusin, dihydroclusin, dihydrocubebin 
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Pharmacological Activity 
Anti- oxidant activity 
Anti-inflammatory activities 
4.FNuhrhzp xkk; (Hyoscyamus niger.Linn) 
Other regional names: 
Eng :  Black henbane , Hanbaneseeds 
Mal :  Kurasani(omum) 
Tel :  Kurasani oamamu 
 
Rit : fhHg;G , rpWifg;G 
jd;ik : ntg;gk; 
gphpT : fhHg;G 
 
nra;if:  
,rptfw;wp 
jhJntg;gfw;wp 
     Jaulf;fp 
cwf;fKz;lhf;fp 
 
nghJFzk;: 
ntF%j; jpuk;thjk; tPhpael; lk;Gz; 
cFNgjp Al;fLg;gp NdhNl–kpFfug;ghd; 
jPuhf; fgkpitNghk; nra;aF Nuhrhdpnad;why; 
thuh kaf;fKW khy;. 
   -mfj;jpaH Fzthflk; 
Taxonomical classification 
 Kingdom          -  Plantae 
 Subkingdom    -  Tracheobionta  
 Division           -  Magnollophyta  
 Class                -   Dicotyledons  
Order                -  Solanales  
Family              -  Solanaceae  
Genus              -  Hyoscyamus  
            Species            -  niger 
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Botanical description 
                 An erect, viscidly hairy, foetid annual or biennial, up to 5 ft. Leaves radical and 
cauline, coarsely dentate to pinnately lobed; flowers yellowish green, sessile or sub-sessile, 
in terminal scorpioidal cymes; pyxidium, 0.5 in diam.; seeds numerous, minute, oval or 
slightly kidney – shaped, c. 1.5 mm. Long, brown marked with fine but conspicuous 
reticulations.  
Chemical constituents: 
         Hyoscyamine, Hyoscine, Scopolamine, Hyosciprin, Cholin, Fatty oil, Mucilage, 
Albumen and Potassium nitrate 2 p.c.  
Pharmacological activity: 
             Anti-inflammatory activity 
            Anti-histaminic activity 
5.fLFNuhfpzp (Picrorhiza kurroa pennell) 
Other regional names: 
Eng  :  Picrorhiza 
Mal  :  Katukurohini, katurohini 
Tel  :  Katki 
 
Rit    - ifg;G ,  fhh;g;G 
     tPhpak;   - ntg;gk; 
gphpT    - fhh;g;G 
 
nra;if: 
 grPj;jPJ}z;b 
     Flw;GOtfw;wp 
Kiwntg;gfw;wp 
 
nghJFzk;: 
khe;jQ; Ruikak; thAfug; ghdhkQ; 
Nrh;e;jkyf; fl;LjphpNjhlk; - Nghe;jnghl;Lg; 
Gz;tapW NehapitNghk; nghw;nfhbNa–NgjpAz;lhk; 
jpz;fLF Nuhfpzpf;Fj; Njh;. 
   -mfj;jpaH Fzthflk; 
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Taxonomical classification 
Kingdom          - Plantae 
            Class                -   Dicotyledons  
 Subclass           -  Asteride  
Order                -  Scrophulariales  
Family              -  Scrophulariaceae 
Genus             -  Picrorhiza 
            Species           - kurroa 
 
Botonical description 
 Kutki is known as a picrorhiza in the scientific language.  
 The Picrorhiza species is a small perennial herb. 
 Stem is small, weak, creeping, erect at flowering, leafy, and slightly hairy. 
 Roots are about 5–10 cm long. 
 Rhizomes are jointed and zigzag, greyish-brown, cylindrical, irregularly curved 
with branching and rooting at the jointed nodes. 
 Leaves are 5–10 cm long, almost radical, sharply serrate, turning black on 
drying 
 
Chemical constituents 
 Three vital bitter glycosides, namely: Picroside I, Picroside II and Kutkoside.  
 Among them both Picroside and Kutkoside are C-9 monoterpenes.  
 Iridoid glycosides having an epoxy moiety present in the cyclopentane ring.  
 Besides, it also contains organic acids, resin, sugar and tannins along with 
cucurbitacin glycosides (highly oxygenated triterpenes), apocycynin androsin, 
D-mannitol, Kutkiol, Kutkisterol, Apocyanin, Phenol glucosides, Androsin, and 
Picein Iridoid glycosides, Kutkin, Picroside I, II, III, IV, V, Kutkoside, 
Picrorhizin 
Pharmacological activity 
 Immunomodulatory activity 
 Anti asthmatic activity 
 Digestive activity 
 Anti inflammatory 
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 Hepato protectivity 
      (http://www.ijprbs.com/issuedocs/2013/8/IJPRBS%20285.) 
6.fLf;fha; (Terminalia chebula Retz) 
Other regional names: 
Eng :  Ink nut , Chebulic myrobalan 
Mal :  Katukkai 
Tel :  Karak- kaya 
 
Rit  - Jth;g;G, ,dpg;G, fhHg;G, Gspg;G,ifg;G 
     tPhpak; - ntg;gk; 
gphpT  - ,dpg;G 
 
nra;if: 
     Njhw;Waulf;fp  
nghJFzk;: 
fLf;fhAe; jhAq; fUjpnyhd;nwd; whYk; 
fLf;fha;j; jha;f;fjpfq; fhz;eP - fLf;fha;Neha; 
Xl;bAlw;Nww;Wk; cw;wtd;idNahRitfs; 
Cl;LAlw; Nww;WK te;J. 
        -mfj;jpaH Fzthflk; 
 
Taxonomical classification 
Kingdom         -  Plantae 
Subkingdom    -  Tracheophyta 
Division -  Magnoliophyta 
Class  -  Dicotyledons 
Order  -  Myrtales 
Family  -  Combretaceae 
Genus  -  Terminalia  
Species -  chebula 
 
 
 
 
60 
 
Botanical description 
        The tree is tall about 50-80 feet in height. It has round crown and spreading branches. 
The bark is dark brown with some longitudinal cracks. Leaves are ovate and elliptical, with 
two large glands at the top of the petiole. The flowers are monoecious, dull white to yellow, 
with a strong unpleasant odour, borne in terminal spikes or short panicles. The flowers 
appear May-June, the fruits July-December. The fruit or drupe is about 1-2 inches in size. It 
has five lines or five ribs on the outer skin. Fruit is green when unripe and yellowish grey 
when ripe. Fruits were collected from January to April, fruit formation started from 
November to January. 
Chemical constituents 
        The fruits of T. chebula is rich in tannins (about 32%-34%) and its content varies with 
geographical distribution. The tannins of T. chebula are of pyrogallol (hydrolysable) type. A 
group of researchers found 14 components of hydrolysable tannins (gallic acid, chebulagic 
acid, punicalagin, chebulanin, corilagin, neochebulinic acid, ellagic acid, chebulinic acid, 
1,2,3,4,6-penta-O-galloyl-β-D-glucose, 1,6-di-o-galloyl-D-glucose, casuarinin, 3,4,6-tri-o-
glloyl-D-glucose, terchebulin) from T. chebulafruits. Other constituents include phenolics 
such as chebulinic acid, ellagic acid and anthraquinones. Some of the other minor 
constituents were polyphenols such as corilagin, galloyl glucose, punicalagin, terflavin A, 
maslinic acid. Besides, fructose, amino acids, succinic acid, betasitosterol, resin and 
purgative principle of anthraquinone are also present.Flavonol, glycosides, triterpenoids, 
coumarin conjugated with gallic acids called chebulin as well as other phenolic compounds 
were also isolated. Twelve fatty acids were isolated from T. chebula of which palmitic acid, 
linoleic acid and oleic acid were main constituents. Triterpenoid glycosides such as 
chebulosides I and II, arjunin, arjunglucoside, 2α-hydroxyursolic acid and 2α-
hydroxymicromiric acid also have been reported. The leaves were found to contain 
polyphenols such as punicalin, punicalagin, terflavins B, C, and D. The plant is found to 
contain phloroglucimol and pyrogallol, along with phenolic acids such as ferulic, p-
coumaric, caffeic and vanillic acids. Oil extracted from kernels yielded palmitic, stearic, 
oleic, linoleic, behenic and arachidic acids. 
Pharmacological activity 
 Antioxidant and free radical scavenging activity 
 Anticarcinogenic activity 
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 Antimutagenic, radioprotective and chemopreventive activity 
 Anti-inflammatory and anti-arthritic activity 
 Wound healing activity 
 Immunomodulatory activity 
 Anti-allergic activity 
 Cytoprotective activity 
  (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631759/) 
7.fUQ;rPufk; (Nigella sativa .Linn) 
Other regional names: 
Eng  :  Black Cumin 
Mal  :  Karichirakam 
Tel  :  Nalla-jilakarra 
 
Rit    - ifg;G  
     tPhpak;   - ntg;gk; 
gphpT    - fhh;g;G 
 
nra;if: 
 grPj;jPJ}z;b 
     twl;rpafw;wp 
GOf;nfhy;yp 
J}f;Fzpg;GOf;nfhy;yp 
 
nghJFzk;: 
fUQ; rPufj;jhd; fug;gndhL Gz;Zk; 
tUQ;rpuha;g; gPerK khw;Wk; - mUe;jpdhy; 
fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
tha;r;r kUe;njdNt it. 
   -mfj;jpaH Fzthflk; 
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Taxonomical classification 
Kingdom         -  Plantae 
Subkingdom    -  Viridiplantae 
Division -  Tracheophyta 
Class  -  Magnoliopsida 
Order  -  Ranunculales 
Family  -  Ranunculaceae 
Genus  -  Nigella   
Species -  sativa 
 
Botanical description 
            Nigella sativa, which is also known as black cumin and panacea. N. sativa is a 
member of the Ranunculaceae family; it is approximately 20–30 cm in height and has 
white, yellow, pink, light blue or red flowers. The fruit is a large and 
inflated capsule composed of three to seven united follicles, each containing 
numerous seeds. 
Chemical constituents 
           The plant contains various compounds including nonvolatile oils, alkaloids, saponin, 
oleic and linoleic acids, thymoquinone (TQ), p-cymene, t-anethole, carvacrol, 4-terpineol, 
and longifoline. Other components include sterols, phospholipids, tannins, resins, hydroxyl 
ketones, polyphenols, tocopherols, and vitamins.TQ is an important pharmacologically 
active component and several effects of N. sativa are attributed to this ingredient. 
Pharmacological effects of N. sativa such as antioxidant, analgesic, anti-inflammatory, 
antimutation, anti-liver and anti-kidney toxicity, antidiabetic, antiulcer, and 
immunoprotective properties have also been reported in several studies. 
  (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737945/) 
PHARMACOLOGICAL ACTIVITY 
 Antiinflammatory 
 Analgesic 
 Antipyretic 
 Antimicrobial and Antineoplastic activity.  
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8.Rf;F (Zingiber officianale , Rosc) 
Other regional names: 
Eng :  Green ginger-fresh root of dry 
Mal :  Inji, chukka 
Tel :  Allama 
 
Rit  - fhh;g;G 
     tPhpak; - ntg;gk; 
gphpT  - fhh;g;G 
 
 
 
nra;if: 
 grPj;jPJ}z;b 
     nrhpg;Gz;lhf;fp 
     ckpo;ePHg;ngUf;fp 
 
nghJFzk;: 
#iyke;jk; neQ;nrhpg;G NjhlNkg; gk;koiy 
%yk; ,iug;gpUky; %f;FePh; - thyfg 
Njhlkjp rhue; njhlh;thj Fd;kePh;j; 
Njhlk;M kk;Nghf;FQ; Rf;F. 
   -mfj;jpaH Fzthflk; 
 
Taxonomical classification 
Kingdom       -  Plantae 
Clade            -  Angiosperms 
Clade           -   Monocots 
Order          -  Zingiberales 
Family       -  Zingiberaceae 
Genus        -  Zingiber 
Species       -  officinale 
 
Botanical description 
The ginger plant, Zingiber officinale, has a biennial or perennial, creeping rhizome, 
and an annual stem, which rises two or three feet in height, is solid, cylindrical, erect, and 
enclosed in an imbricated membranous sheathing. The leaves are lanceolate, acute, smooth, 
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five or six inches long by about an inch in breadth, and stand alternately on the sheaths of 
the stem. The flower-stalk rises by the side of the stem from six inches to a foot, and, like it, 
is clothed with oval acuminate sheaths; but it is without leaves, and terminates in an oval, 
obtuse bracteal, imbricated spike. The flowers are of a dingy yellow color, and appear two 
or three at a time between the bracteal scales. 
 
Chemical constituents 
Numerous active ingredients are present in ginger including terpenes and oleoresin 
which called ginger oil. Ginger also constitutes volatile oils approximately 1% to 3% and 
non-volatile pungent components oleoresin . The major identified components from terpene 
are sesquiterpene hydrocarbons and phenolic compounds which are gingerol and shogaol  
and lipophilic rhizome extracts, yielded potentially active gingerols, which can be converted 
to shogaols, zingerone, and paradol . 
 
Pharmacological activity  
 Antioxidant activity 
 Anti-inflammatory activity 
 Anti-tumour activity 
 Hepato-protective effect 
 Anti-microbial activity 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106649/) 
9.thYSit (Celastrus paniculatus. Wild) 
Other regional names: 
Eng  :  Climbing staff plant 
Mal  :  Cherrupunnari 
Tel  :  Mal- kanguni-vittulu 
 
            Rit    - ifg;G  
tPhpak;   - ntg;gk; 
gphpT    - fhh;g;G 
 
nra;if: 
ehbAukhf;fp 
tpaHitngUf;fp 
clw;Nww;wp 
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nghJFzk;: 
tapw;Wf; fLg;Gtyp khwhf; fpuhzp 
gapj;jpaq; fhrky ge;jQ; - rapf;fnthzhr; 
#jpfh thjKk; Nghe; njhy;th YSittpijf; 
Fhjpet rpj;jh; nkhopahk;. 
   -mfj;jpaH Fzthflk; 
Taxonomical classification 
Kingdom         -  Plantae 
Subkingdom    -  Tracheobionta 
Division -  Magnliophyta 
Class  -  Magnoliopsida 
Order  -  Celastrales 
Family  -  Celestraceae 
Genus  -  Celastrus  
Species -  paniculatus 
 
Botonical description 
               The base stem of this shrub grows up to 10 centimeters in diameter and 6 meters in 
length. Being a rambler by nature, it produces many woody branches that cling to 
surrounding flora for support. The stem has a rough, pale or reddish brown exfoliating bark 
covered densely with small elongated white lenticels. The inner bark is light and cork like 
with yellow sapwood. The leaves are simple, broad, and oval, obovate or elliptic in shape, 
leathery and smooth, alternately arranged on short petioles with toothed margins1 . They 
grow on singular stems ranging from light to dark green color. The flowers are tiny with 3.8 
mm diameter, whitish green to yellow green in color and grow on the top of the main stalk 
in terminal drooping panicles of 5-20 cm length. Capsules of the plant are depressed, 
globose, tri-lobed, bright yellow colored with 1-1.3 cm diameter, containing 3-6 seeds per 
capsule/ seed pod which are enclosed by an orange-red aril. The seeds are small and oval 
shaped growing in round pods that gradually change from a light yellow to a deep red color 
as they mature 
Chemical constituents 
 Leaves 
Saponin 
 Root bark 
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β-sitosterol, Celastrol, Pristimerin, Zeylasterone, Zeylasteral; Terpenes 
 Seed / Seed oil 
 
Acetic and benzoic acids in addition to other fatty acids; crystalline substance 
tetracasanol and sterol14, 15; Alkaloids Celastrine and Paniculatin. 
 
Pharmacological activity 
 Analgesic and Anti-inflammatory 
 Antioxidant 
 Hypolipidaemic 
 Wound healing activity 
 Anti-bacterial activity 
 Anti-fungal activity 
                     (http://www.ijpbs.net/vol-3/issue-3/pharma/33.) 
10.muj;ij (Alpinia officinarum.Linn) 
Other regional names: 
Eng :  Galangal the lesser 
Mal :  Aratha 
Tel :  sanna-rashtramu 
 
Rit  -  fhh;g;G  
tPhpak; - ntg;gk; 
gphpT  - fhh;g;G 
 
nra;if: 
ntg;gfw;wp 
Nfhioafw;wp 
grPj;jPJ}z;b 
 
nghJFzk;: 
njhz;ilapw;fl; Lq;fgj;ijj; J}uj; Juj;jptpLk; 
gz;ilr;rP jj;ijg; gwf;fbf;Fk; - nfz;iltpop 
kpd;id! fug;gidNt whf;Fk; grpnfhLf;Fk; 
nrhd;Ndhk; muj;ijr; Rfk;. 
   -mfj;jpaH Fzthflk; 
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Taxonomical classification: 
Kingdom   -  Plantae 
Division    -  Angiosperms 
Class         -  Monocots 
Order        -  Zingiberales 
Family      -  Zingiberaceae 
Genus       -  Alpinia 
Species     -  officinarum 
 
Botonical description 
The plant is a rhizomatous, perennial herb, and attains a height of about 1.5–2.5 m. 
The rhizome is very prominent and aromatic. Externally, it is reddish brown-white and 
internally reddish-white. Leaves are leathery, about 30–60 cm long and 10–15 cm, glossy 
on both surfaces, lanceolate and smooth, with white margins. 
 
Chemical constituents 
 Benzylacetone (26.77%), 1,7-diphenyl-5-hydroxy-3-heptanone (17.78%), 
Guaiacylacetone (10.03%) and Benzenepropanal (7.42%). The essential oil 
of A. officinarum rhizomes (LD50 = 20.71 μg/adult). 
 1-phenyl-4-(16,17-dimethyl-9,13-octadiene)-5-isopentenyl-7-(4"-methoxyl-
3"-hydroxyl-phenyl)-3-heptanone.  
 5-hydroxy-1,7-diphenyl-3-heptanone, 1, 7-diphenyl-4-hepten-3-one,  
galangin-3-methyl ether  and pinocembrin. 
                            (https://www.ncbi.nlm.nih.gov/pubmed/28420198) 
 
Pharmacological Activity 
Anti-inflammatory, Antioxidant, and Anticancer properties. 
         (www.phcogrev.com/article.asp?issn=0973-7847;year=2017;volume=11) 
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11.jpg;gpyp (Piper longum) 
Other regional names: 
Eng :  Long pepper 
Mal :  Thippili 
Tel :  Pippilu 
 
Rit : ,dpg;G  
jd;ik : ntg;gk; 
gphpT : ,dpg;G 
 
nra;if:  
ntg;gKz;lhf;fp 
mfl;Lthafw;wp 
 
nghJFzk;: 
jpg;gpypapd; wz;LyQ; rpNyj;kj;ijg; Nghf;fptpLk; 
cg;gprj;ij Nkfj;ij Xl;Lq;fhz; - jg;ghky; 
thj Rue;jzpf;Fk; khfgNuh fe;njhiyf;Fk; 
jhJit tsh;g;gpf;FQ; rhw;W. 
   -mfj;jpaH Fzthflk; 
 
Taxonomical classification 
Kingdom    -  Plantae 
Division     -  Magnoliophyta 
Class          -   Magnoliopsida 
Order         -  Piperales 
Family       -   Piperaceae 
 Genus       -   Piper 
 Species     -   longum 
 
Botanical description: 
           It is a slender, aromatic, perennial climber, with woody roots and numerous wide 
ovate, cordate leaves. The inflorescence is a cylindrical, pedunculate spike, the female 
flower is up to 2.5 cm long and 4-5 mm in diameter but the male flower is larger and 
slender. The fruits are small, ovoid berries, shiny blackish green, embedded in fleshy spikes  
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Chemical constitution: 
             Piper longum contain piperine as the major and active constituent, Thepiperine 
content is 3- 5% (on dry weight basis) in Piper longum. The fruits gave positive result for 
presence of starch, protein and alkaloids, volatile oils, saponins, carbohydrates, and 
amygdalin and negative result for tannins. 
          Methyl piperine, pipernonaline, piperettine, asarinine, pellitorine, piperundecalidine, 
piperlongumine, piperlonguminine, retrofractamide A, pergumidiene, brachystamide-B, a 
dimer of desmethoxypiplartine, N-isobutyl decadienamide, brachyamide-A, brachystine, 
pipercide, piperderidine, longamide, dehydropipernonalinepiperidine, and 
tetrahydropiperine. Piperine, piperlongumine, tetrahydropiperlongumine, 
trimethoxycinnamoyl-piperidine, and piperlonguminine have been found in the root. 
Pharmacological activity: 
 Anti-inflammatory activity 
 Immunomodulatory activity 
 Antioxidant activity 
12.,z;L (Acacia pennata,Lam.) 
Other regional names: 
Eng :  straggling prickly shrub; Eight pinnate soap pod 
Rit  -  fhh;g;G  
tPhpak; - ntg;gk; 
gphpT  - fhh;g;G 
 
nra;if: 
Nfhioafw;wp 
ntg;gKz;lhf;fp 
 
nghJFzk; 
gPerj;ijg; Nghf;Fk; ngUfpaNjhh; ePNuw;wk; 
jhdrpf;fr; nra;AkpJ rj;jpaq;fhz; - thdirf;Fk; 
kz;ilf; Filr;ry; kUTKf rd;dpAk; Nghk; 
gz;ilAw;w ,z;bDf;Fg; ghh;. 
       -mfj;jpaH Fzthflk; 
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Taxonamical classification  
Kingdom   -   plantea 
Clade        -  Angiosperms 
Clade        -  Eudicots 
Order        -  Fabales 
Family      -  Mimosaceae 
Genus       -  Accacia 
Species     -  pennata 
 
 Botonical description:  
Acacia pennata is a scandent shrub with scattered numerous prickles. 
Leaves are bipinnately compound. Pinnas are in 8 to 20 pair and leaflets are more than 30 
pair. Petiole is 2 cm long, with a plate shaped gland near the middle or the base. Rachis is 
grooved, obscurely prickled, with glands opposite to two uppermost pairs of pinnae. 
 
Chemical constititions: 
The leaves of plant contain Octadecadienoic, octadecanoic, palmitic and 
pentadecanoic acids; lupeol, a-spinasterol, beta- sitosterol and tannins. 
The bark contains tannin 9%, lupeol and alpha-spinasterol. 
Stem yields sitosterol. 
 
Pharmacological activity: 
 Anti-inflammatory activity 
 Antinociceptive activity 
                          (https://www.ncbi.nlm.nih.gov/pubmed/15763384) 
13.rPdpf;fw;fz;L (Saccharum officinarum , Linn) 
Other regional names: 
Eng :  sugarcane , noble cane 
Mal :  karinba 
Tel :  cherukku Kanupula-cherukku 
 
Rit  -  ,dpg;G  
tPhpak; - rPjk; 
gphpT  - ,dpg;G 
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nra;if: 
mOfyfw;wp 
cs;soyhw;wp 
 
nghJFzk; 
<wpd; jbg;G kpUkYk;gy; the;jpfSQ; 
rPWfg Kl;bdKQ; NruhNj - Njwpaew; 
nrhw;fz; bsq;Fapy;fs; #o kltdNk! 
fw;fz; nldTiuf;Fq; fhy;;. 
  -mfj;jpaH Fzthflk; 
 
Taxonomical cassification 
Kingdom    -   Plantae 
Subkingdom  -   Viridiplantae 
Division       -  Tracheophyta 
Order          -   Poales 
Family        -   Poaceae 
Genus  -   Saccharum 
Species -   officinarum 
 
Botanical description 
Saccharum officinarum is a perennial plant that grows in clumps consisting of a 
number of strong unbranched stems. A network of rhizomes forms under the soil, which 
sends up secondary shoots near the parent plant. The stems vary in color being green, 
pinkish or purple and can reach 5 cm (16 ft) in height. They are jointed, nodes being present 
at the bases of the alternate leaves. The internodes contain a fibrous white pith, immersed in 
sugary sap. The elongated, linear, green leaves have thick midribs and saw-toothed edges 
that grow to a length of about 30 to 60 cm (12 to 24 ins) and width of 5 cm (2.0 ins). The 
terminal inflorescence is a panicle up to 60 cm (24 ins) long, a pinkish plume that is 
broadest at the base and tapering toward the top. The spikelets are borne on side branches 
and are about 3 mm (0.12 ins) long and are concealed in tufts of long, silky hair. The fruits 
are dry and each one contains a single seed.Sugarcane harvesting typically occurs before the 
plant flowers, as the flowering process causes a reduction in sugar content 
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Chemical costituents 
Phytochemicals including phenolic compounds, plant sterols, and policosanols.  
 
Pharmacological activity 
 Anti-inflammatory effect 
 Antithrombotic activity 
 Antihepatotoxic activity 
 Analgesic activity 
                               (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441162/) 
14. ntl;bNth; ( Vetiveria  zizanioides .Linn) 
Other regional names: 
Eng :  Cuscus grass, vetiver , Khas- khas, khus-khus 
Mal :  vettiveru  
Tel :  vatti very 
Avvuru-goddi-veru 
 
Rit  -  ,dpg;G  
tPhpak; - rPjk; 
gphpT  - ,dpg;G 
 
nra;if: 
cukhf;fp 
,rptfw;wp 
ntg;gfw;wp 
 
nghJFzk; 
gpj;jtp jhfk; rrpfh kpyq;fiwg; gpj;jkdw; 
wj;jpL Fl;lQ; rpuNeha; fskb jhJel;l 
kj;jk dw;Gz; ldg;Gz;td; %h;r;irthptpopNeha; 
tpj;jpu Nkfj;jpd; fl;bAk; Nghk; ntl;b NthpDf;Nf. 
   -mfj;jpaH Fzthflk; 
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Taxonomical classifications: 
Kingdom    -   Plantae 
Subkingdom -  Viridiplantae 
Division       -  Manoliophyta 
Class          -  Monocotyledons 
Order         -   Cyperales 
Family        -   Poaceae 
Genus         -   Vetiveria 
Species       -  ziznioides    
    
Botanical description: 
Vetiver grows to 150 centimetres (5 ft) high and form clumps as wide. Under 
favorable conditions, the erect culms can reach 3m in height.The stems are tall and the 
leaves are long, thin, and rather rigid. The flowers are brownish-purple. Unlike most 
grasses, which form horizontally spreading, mat-like root systems, vetiver's roots grow 
downward, 2 metres (7 ft) to 4 metres (13 ft) in depth.
 
The root system of vetiver is finely structured and very strong. It can grow 3 metres 
(10 ft) to 4 metres (13 ft) deep within the first year. Vetiver has 
neither stolons nor rhizomes. Because of all these characteristics, the vetiver plant is 
highly drought-tolerant and can help to protect soil against sheet erosion. In case 
of sediment deposition, new roots can grow out of buried nodes. 
Chemical constituents: 
Vetiver oil or khus oil is complex oil, containing over 100 identified components, 
typically  
benzoic acid  furfurol  
vetivene  vetivenyl vetivenate  
terpinen-4-ol  5-epiprezizane  
khusimene α-muurolene  
khusimone Calacorene  
β-humulene  α-longipinene  
γ-selinene  δ-selinene  
δ-cadinene  valencene  
calarene,-gurjunene α-amorphene  
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epizizanal 3-epizizanol 
khusimol Iso-khusimol  
valerenol  β-vetivone  
α-vetivone  vetivazulene 
 
 
Pharmacological activity 
 
 
Antioxidant Activity 
Antibacterial Activity 
Antidepressant Activity 
Hepatoprotective Activity 
 
15. mjpkJuk; ( Glycyrrhiza glabra.Linn) 
Other regional names: 
Eng : Jequitity ; Indian or Jamaica liquorice 
Mal :  Ati-madhuram , Iratti-Madhuram 
Tel :  Ati- madhukam 
          Yasti-Madhukam 
  
           Rit  - ,dpg;G  
     tPhpak; - rPjk; 
gphpT  - ,dpg;G 
 
nra;if: 
 twl;rpafw;wp 
     Nfhioafw;wp 
 cs;soyhw;wp 
     cukhf;fp 
     kykpsf;fp 
 
nghJFzk;: 
fj;jpahp Kg;gpzpahy; tUGz; jhfq; 
 fz;Nzha;cd; khjk;tpf;fy; typntz; Fl;lk; 
gpj;jnkYk; GUf;fp fphpr;ruk; Mth;j;j 
 gpj;jkj %h;r;irtpl ghfk; ntg;ge; 
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jj;jptU thjNrh zpjq;fh khiy 
 rUttplq; fhkpaNeha; jhJ el;lq; 
Fj;jpUky; Mrpaq;fk; ,jo;Neha; ,e;J 
 Fag;GZk;Nghk; kJ}fnkdf; $Wq; fhNy. 
   -mfj;jpaH Fzthflk; 
Taxonomic classification: 
Kingdom      -  Plantae 
Clade            -  Angiosperms 
Clade            -  Eudicots 
            Order        -  Fabales 
Family      -  Fabaceae 
Genus       -  Glycyrrhiza 
Species     -  glabra 
 
Botanical description: 
It is a herbaceous perennial, growing to 1 m in height, with pinnate leaves about 7–
15 cm (2.8–5.9 in) long, with 9–17 leaflets. The flowers are 0.8–1.2 cm (1⁄3–
1⁄2 in) long, 
purple to pale whitish blue, produced in a loose inflorescence. The fruit is an oblong pod, 2–
3 cm (
3⁄4–1 
1⁄6 in) long, containing several seeds.The roots are stoloniferous 
 
The licorice plant is erect, standing about 1.5 meters tall with spikes bearing lilac-
colored flowers with bean-like pods containing three or four seeds 
 
The main root (taproot) descends up to a meter into the ground and sends out a 
network of rhizomes. These roots and rhizomes are harvested after three to five years. 
 
The rhizomes have a woody appearance with a brown skin and yellow, fibrous 
interior. 
 
Chemical constituents 
The roots of Glycyrrhiza glabra Linn.contain glycyrrhizin, which is a saponin that is 
60 times sweeter than cane sugar; Flavonoid rich fractions include liquirtin, isoliquertin 
liquiritigenin and rhamnoliquirilin and five new flavonoids- glucoliquiritin apioside, 
prenyllicoflavone A, shinflavanone, shinpterocarpin and 1-metho-xyphaseolin isolated from 
dried roots 
13
. Isolation and structure determination of licopyranocoumarin, 
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licoarylcoumarin, glisoflavone and new coumarin-GU-12 also isolated. Four new 
isoprenoid-substituted phenolic constituents – semilicoisoflavone B, 1-methoxyficifolinol, 
isoangustone A, and licoriphenone isolated from roots. 
 
A new prenylated isoflavan derivative, kanzonol R was also isolated . The presence 
of many volatile components such as pentanol, hexanol, linalool oxide A and B, tetramethyl 
pyrazine, terpinen-4-ol, α-terpineol, geraniol and others in the roots is reported. Presence of 
propionic acid, benzoic acid, ethyl linoleate, methyl ethyl ketine, 2, 3-butanediol, 
furfuraldehyde, furfuryl formate, 1-methyl-2-formylpyrrole, trimethylpyrazie, maltol and 
any other compounds is also isolated from the essential oil . 
 
The Indian roots show various 2-methyliso - flavones, and an unusual coumarin, C 
liquocoumarin, 6 - acetyl- 5, hydroxy- 4 - methyl coumarin. Asparagine is also found. 
Glycyrrhizin (glycyrrhizic acid; glycyrrhizinate) constitutes 10–25% of licorice root extract 
and is considered the primary active ingredient. Glycyrrhizin is a saponin compound 
comprised of a triterpenoid aglycone, glycyrrhetic acid (glycyrrhetinic acid; enoxolone) 
conjugated to a disaccharide of glucuronic acid. 
 
Both glycyrrhizin and glycyrrhetic acid can exist in the 18α and 18β stereoisomers. 
As a tribasic acid, glycyrrhizin can form a variety of salts and occurs naturally in licorice 
root as the calcium and potassium salt 
Pharmacological activity 
 
Antitussive, expectorant,Antibacterial, Antioxidant, Antimalarial, Antispasmodic, Anti-
inflammatory and Anti-hyper glycemic properties. 
 
16. Njtjhuk; ( Cedrus deodara.G.Don.)  
Other regional names: 
Eng : Himalayancedar,deodar 
Mal : Thevatharam 
Tel :  Davadaru; 
 
Rit  - rpWifg;G 
tPhpak; - ntg;gk; 
gphpT  - fhh;g;G 
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nra;if: 
mfl;Lthafw;wp 
 
nghJFzk;: 
Njtjh uf;Fze;jhd; Nrh;j;Jtsh; gPdprj;ijf; 
fhtfj;jp Nyhl;Lq; fug;gyNt–khtyth; 
nrhy;Yk;G uhzRunkhLeP Nuw;wj;ij 
nty;Y kdw;wzpf;F nka;. 
   -mfj;jpaH Fzthflk; 
 
Taxonomical classifications: 
           Kingdom    -  plantae 
Division     -  Pinopyta 
Class          -  Pinosida 
Order        -  Pinales 
Family       -  Pinacae 
Genus       -  Cedurus 
Species     -  deodra 
 
Botanical description: 
It is a large evergreen coniferous tree reaching 40–50 m (131–164 ft) tall, 
exceptionally 60 m (197 ft) with a trunk up to 3 m (10 ft) in diameter. It has a conic crown 
with level branches and drooping branchlets. 
           The leaves are needle-like, mostly 2.5–5 cm (0.98–1.97 in) long, occasionally up to 
7 cm (2.8 in) long, slender (1 mm (0.039 in) thick), borne singly on long shoots, and in 
dense clusters of 20–30 on short shoots; they vary from bright green to glaucous blue-green 
in colour. The female cones are barrel-shaped, 7–13 cm (2.8–5.1 in) long and 5–9 cm (2.0–
3.5 in) broad, and disintegrate when mature (in 12 months) to release the winged seeds. The 
male cones are 4–6 cm (1.6–2.4 in) long, and shed their pollenin autumn. 
Chemical constituents:  
      The wood contains cedeodarin, ampelopsin, cedrin, cedrinoside, and deodarin (3′,4′,5,6-
tetrahydroxy-8-methyl dihydroflavonol.  
 
             The main components of the needle essential oil include α 
terpineol (30.2%), linalool (24.47%), limonene (17.01%), anethole (14.57%), caryophyllene
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  (3.14%), and eugenol (2.14%). The deodar cedar also contains lignans and the phenolic 
sesquiterpene himasecolone, together with isopimaric acid. Other compounds have been 
identified, including (−)-matairesinol, (−)-nortrachelogenin, and a 
dibenzylbutyrolactollignan (4,4',9-trihydroxy-3,3'-dimethoxy-9,9'-epoxylignan). 
 
Pharmacological activity: 
 Analgesic  
 Anti inflammatory activity 
 Anxiolytic  
 Anti convulsant activity of alcoholic extract 
 Anti ulcer  
 Anti fungal effect 
17. ey;nyz;nza; ( Sesamum indicum.Linn) 
Other Regional Names: 
Eng : Gingeli oil plant, gingelly , Sesame 
Mal : Karuella 
Tel :  Nuvulu 
 
Rit  - ,dpg;G  
      tPhpak; - ntg;gk; 
gphpT  -  ,dpg;G 
 
nra;if: 
 twl;rpafw;wp 
     cs;soyhw;wp 
 
nghJFzk;: 
Gj;jpeadf;Fsph;r;rp G+hpg;G nka;g;GsfQ; 
rj;Jtq; fe;jp jdpapsik–nkj;jTz;lhq; 
fz;Nzha; nrtpNeha; fghytoy; fhrNeha; 
Gz;Nzha;Ngh nkz;nza;ahw; Nghw;W. 
   -mfj;jpaH Fzthflk; 
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Taxonomicl classification 
Kingdom         -  Plantae 
Subkingdom    -  Viridiplantae 
Division -  Tracheophyta 
Class  -  Magnoliopsida 
Order  -  Lamiales 
Family  - Pedaliaceae 
Genus  -  Sesamum   
Species -  indicum 
 
Botanical description 
 
                The Sesamum indicum L., is a plant of the Pedaliaceae family and Sesamum 
genus, annual herb, high 80-180cm. Stems erect, 4-angled, angular, base slightly lignified, 
unbranched, pubescent. Leaves opposite, or upper ones alternate; petiole 1-7cm long; leaf 
blade ovate, oblong or lanceolate, 5-15cm long, 1-8cm wide, apex acute or acuminate, base 
cuneate, entire, Sawtooth or lower leaves 3 lobed, surface greenish, abaxially pale green, 
both surfaces glabrous or slightly white-fleshed. Flowers solitary, or 2-3 flowers born in 
leaf axils, 1-1.5 cm in diam.; calyx slightly connate, green, 5-lobed, lobes lanceolate, 5--10 
cm long, pilose; corolla tube, lip-shaped, long 1.5-2.5cm, white, purple or yellow, halo, 
lobes rounded, lateral puberulous; stamens 4, inserted at base of corolla tube, anthers 
yellow, sagittate; pistil 1, carpel 2, ovary conic At the beginning, it was false in 4 rooms, 
and it was mature in 2 rooms. The style was linear and the stigma was split. Capsule elliptic, 
2-2.5cm long, 4-sided or 6-8-sided, longitudinally fissile, early green, dark brown after 
maturity, pubescent. Most seeds are ovate, flat on both sides, black, white or light yellow. 
Flowering from May to September, fruiting period from July to September. 
 
Chemical constituents 
 
Proteins and fat oils 
Momor-cerebroside , soya-cerebroside II , 1-O-beta-D-glucopyranosyl-(2S, 3S, 4R, 
5E,9Z)-2-N-(2'-hydroxytetracosanoyl) 1,3,4-trihydroxy-5,9-octadienine , 1-O-beta-D-
glucopyranosyl-(2S, 3S, 4R, 8Z)-2-N-(2' R) 2'-hydroxytetracosanoyl) 3,4-dihydroxy-8-
octadene , (2S, 1" S) -aurantiamide acetate , benzyl alcohol-O-(2'-O-beta-D-xylopyranosyl, 
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3'-O-beta-D-glucopyranoside)-beta-D-glucopyranoside , beta-sitosterol , daucosterol  and 
D-galacititol . 
 
Pharmacological activity 
 Antioxidant 
 Wound healing activity 
 Hepatoprotective  activity 
 Anticancer 
 Antiaging and Anticoagulant activities. 
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FIGURES OF RAW DRUGS 
               
Fig 3.4.  Amukkara (withania somnifera)  Fig 3.5.  Vaal milagu (Piper cubeba) 
 
 
 
        
 
 
 
Fig 3.6 Kurosani omam (Hyosymus niger)  Fig 3.7 Parangipattai (Smilax china) 
 
 
 
             
 
 
    
Fig 3.8  Kadugurohini ( Picrorhiza kurroa)  Fig 3.9 Kadukkai (Terminalai chebula) 
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Fig 3.10 Karunseeragam(Nigella sativa)                  Fig 3.11 Chukku(Zingeber officinalis) 
 
 
 
 
 
 
 
Fig 3.12 Vaaluluvai (Celatrus paniculatus)             Fig 3.13 Arathai  (Alpini officinarum) 
 
 
 
 
 
 
 
Fig 3.14 Thippili  (Piper longum)       Fig 3.15  Indu (Accacia penneta) 
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Fig 3.16 Seenikarkandu (Saccharum officinarum)    Fig 3.17 Vettiver   (Vettiveria ziznioides) 
 
 
 
 
 
 
 
 
Fig 3.18 Adhimadhuram(Glycyrrhiza glabra)   Fig 3.19 Devadharam(Cedrus deodara)  
 
 
 
 
 
 
 
 Fig 3.20 Nallennai (Sesamum indicum) 
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MATERIALS AND METHODS  
Source of Raw Drugs  
The required raw drugs for the trial medicine were purchased from a well reputed 
country raw drug shop and drugs were authenticated by the competent authority of 
department of Medicinal Botany, National Institute of Siddha. After that the raw drugs were 
purified separately then the trial drugs were prepared in Gunapadam laboratory of National 
Institute of Siddha. 
PREPERATION OF TRIAL DRUGS   
                       Internal Medicine:  AMUKKARA CHOORANAM  
                       (Ref : Brahmamuni Karukkadai Soothiram - 380) 
INGREDIENTS  :   
 
          1. Amukkara kizhangu chooranam (Withania somnifera)    -10 Palam (350 Gram) 
          2. Vaalmilagu (Piper cubeba)                                               - 1  Palam  (35 Gram) 
          3. Kurosani omam (Hyoscyamus niger)                               - 1 Palam   (35 Gram) 
          4. Parangipattai  (Smilax china)                                            - 1 Palam   (35 Gram) 
          5. Karumseeragam (Nigella sativa)                                       - 1 Palam   (35 Gram)  
          6. Kadukkai (Terminalia chebula)                                         - 1 Palam   (35 Gram) 
          7. Chukku (Zingiber officinale)                                             - 1 Palam   (35 Gram) 
          8. Kadugu rogini (Picrorhizza scrophulariiflora)                   - 1 Palam   (35 Gram) 
          9. Vaaluluvai (Celastrus paniculatus)                                     - 1 Palam  (35 Gram) 
        10. Arathai (Alpinia galanga)                                                   - 1 Palam   (35 Gram) 
        11.Thippili (Piper longum)                                                       - 1 Palam   (35 Gram) 
        12. Indu (Mimosa rubicaulis)                                                   - 1 Palam   (35 Gram) 
        13. Seeni sarkkarai (Cane sugar)                                              -¼ quantity of the other drug  
 
PURIFICATION OF THE DRUGS : 
   
 Amukkara kizhangu  
The drug was dried , grinded into powder boiled in steam for 3 hours and dried in 
sun light. The powder was again finely ground.           (Cigicha rathna deepam )  
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Parangipattai 
            The drug was dried , grinded into powder boiled in steam for 3 hours and dried in 
sun light. The powder was again finely ground.               (Cigicha rathna deepam ) 
 
Vaal milagu 
          The stalk was removed and dried in sun light.             (Cigicha rathna deepam )  
 
Kurosani omam 
          
 Rubbed with sand and waste materials were removed. 
                                                                          (Marunthu sei iyalum kalaium )          
Karumseeragam 
          
         It is soaked in the lime stone extract and dried.   (Marunthu sei iyalum kalaium ) 
 
Kadukkai 
          The seeds were removed and their outer coverings were taken. 
                                                                                        (Marunthu sei iyalum kalaium ) 
Chukku 
Soaked in limestone water for a period of time ,dry it and the outer layer was peeled off.     
                                          
                                                                                    (Marunthu sei iyalum kalaium )      
Kadugurogini 
The drug was soaked in Neem juice for 3 hours and dried in sun light . 
                                                                                    (Cigicha rathna deepam ) 
Vaaluluvai 
             The seeds were washed in aloevera juice and dried in sun light. 
                                                                                                (Cigicha rathna deepam ) 
Arathai 
 Washed with water and dried.                                    (Cigicha rathna deepam ) 
 
    
Thippili 
 
            Soaked in lime juice and dried.                                  (Marunthu sei iyalum kalaium )  
 
Indu 
          Remove the unwanted material .                                  (Cigicha rathna deepam ) 
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SOURCE OF TRIAL MEDICINE:   
The required drugs was purchased from a well reputed country shop and raw drugs 
were authenticated by the medicinal botanist of National Institute of Siddha. The medicine 
was prepared in Gunapadam lab of National Institute of Siddha after proper purification. 
The prepared medicine was also be authenticated by the Gunapadam Head of the Dept for 
its completeness.All the ingredients mentioned in the formulation was purified as per the 
direction described in the Siddha literature.  
 
PREPARATION  :  
The required quantity of the purified  drugs was taken and grinded into fine powder 
and filtered by vasthrakayam procedure. 
 
  
DOSAGE:          ½ - 1 gram twice a day  
VEHICLE:         Ghee  
DURATION:     45 days  
DISPENSING: The prepared chooranam was dispensed in a pure container with  
                           required details and investigators contact number. 
 External Medicine    : VETTIVER THYLAM. 
            (Ref : Aathma Ratchamirthamennum Vaidhya Sara Sangiragam) 
 
INGREDIENTS  :   
 
          1. Vettiver thool (Vettivera zizanioides)      -10 Palam    (350 Gram) 
          2. Water                                                        - 1 pathakku(10.7 lit) 
          3. Gingelly oil                                              - 1 Padi       (1.34 lit) 
          4. Adhimadhuram (Glycyrrhiza glabra)       - 1/2 Palam  (17.5 Gram) 
          5. Karumseeragam (Nigella sativa)              - 1/2 Palam  (17.5 Gram) 
          6. Devadharam (Cedrus deodra)                   - 1/2 Palam   (17.5 Gram) 
          7. Kadukkai (Terminalia chebula)                - 1/2 Palam   (17.5 Gram) 
 
PREPARATION  : 
            350 grams  of vettiver powder is taken and 10.7 liter of water was added to the 
mixture , boiled and reduced  to 1/8 th of its volume .The above prepared decoction was 
mixed with gingely oil and other powdered ingredients and boiled to obtained the required 
oil. 
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DOSAGE: 100 ml 
DURATION: 45 Days 
 
DISPENSING : The prepared Thylam was dispensed in a pure container with 
                           required details and investigators contact number 
 
PREPARED MEDICINE 
AMUKKARA CHOORANAM 
 
 
 
 
 
 
 
VETTIVER THYLAM 
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Pre clinical studies 
4.1 Physicochemical Analysis 
Particle Size 
            Particle size determination was carried out by optical microscopic method. In which 
the sample were dissolved in the sterile distilled water (app 1/100
th
 dilution). Diluted 
sample were mounted on the slide and fixed with stage of appropriate location. Light 
microscopic image were drawn with scale micrometer to arrive at the average particle size. 
Minimum 30 observations were made to ascertain the mean average particle size of the 
sample. 
Percentage Loss on Drying 
10gm of test drug was accurately weighed in evaporating dish .The sample was 
dried at 105
o
C for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
Determination of Total Ash 
3 g of test drug was accurately weighed in silica dish and incinerated at the furnace a 
temperature 400 ºC until it turns white in color which indicates absence of carbon. 
Percentage of total ash will be calculated with reference to the weight of air-dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute hydrochloric 
acid for 6mins. Then the insoluble matter is collected in crucible and will be washed with 
hot water and ignited to constant weight. Percentage of acid insoluble ash will be calculated 
with reference to the weight of air-dried ash. 
Acid insoluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 mins. The 
insoluble matter is collected in crucible and will be washed with hot water, and ignite for 
15mins at a temperature not exceeding 450ºC. Weight of the insoluble matter will be 
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subtracted from the weight of the ash; the difference in weight represents the water soluble 
ash. Calculate the percentage of water-soluble ash with reference to the air-dried drug. 
Water Soluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
Determination of Alcohol Soluble Extractive 
About 5 g of test sample will be macerated with 100 ml of Alcohol in a closed flask 
for twenty-four hours, shaking frequently during six hours and allowing to stand for 
eighteen hours. Filter rapidly, taking precautions against loss of solvent, evaporate 25 ml of 
the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 105ºC, to constant 
weight and weigh. Calculate the percentage of alcohol-soluble extractive with reference to 
the air-dried drug. 
Alcohol sol extract = Weight of Extract/ Wt of the Sample taken X 100 
Determination of Water Soluble Extractive 
About 5 g of the test sample will be macerated with 100 ml of chloroform water in a 
closed flask for twenty-four hours, shaking frequently during six hours and allowing to 
stand and for eighteen hours. Filter rapidly, taking precautions against loss of solvent, 
evaporate 25 ml of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 
105ºC, to constant weight and weigh. Calculate the percentage of water-soluble extractive 
with reference to the air-dried drug. 
Water soluble extract = Weight of Extract/ Wt of the Sample taken X 100 
Determination of pH 
About 5 g of test sample will be dissolved in 25ml of distilled water and filtered the 
resultant solution is allowed to stand for 30 mins and the subjected to pH evaluation 
Thin Layer Chromatography and High Performance Thin Layer Chromatography: 
1 .TLC Analysis 
                 Test sample was subjected to thin layer chromatography (TLC) as per 
conventional one dimensional ascending method using silica gel 60F254, 7X6 cm (Merck) 
were cut with ordinary household scissors. Plate markings were made with soft pencil. 
Micro pipette were used to spot the sample for TLC applied sample volume 10-micro liter 
by using pipette at distance of 1 cm at 5 tracks. In the twin trough chamber with different 
solvent system Toulene: Ethyl Acetate: Acetic Acid (1.5:1:0.5) After the run plates are 
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dried and was observed using visible light Shortwave UV light 254nm and light long-wave 
UV light       365 nm  
2. High Performance Thin Layer Chromatography Analysis  
             HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to achieve 
precision, sensitive, significant separation both qualitatively and quantitatively. High 
performance thin layer chromatography (HPTLC) is a valuable quality assessment tool for 
the evaluation of botanical materials efficiently and cost effectively. HPTLC method offers 
high degree of selectivity, sensitivity and rapidity combined with single-step sample 
preparation. In addition it is a reliable method for the quantitation of nano grams level of 
samples. Thus this method can be conveniently adopted for routine quality control analysis. 
It provides chromatographic fingerprint of phytochemicals which is suitable for confirming 
the identity and purity of medicinal plant raw materials.   
a ) Chromatogram Development  
            It was carried out in CAMAG Twin Trough chambers. Sample elution was carried 
out according to the adsorption capability of the component to be analysed. After elution, 
plates were taken out of the chamber and dried.     
b) Scanning  
           Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values were 
tabulated. 
TOXIC / HEAVY METAL ANALYSIS BY AAS  
Methodology 
               Atomic Absorption Spectrometry (AAS) is a very common and reliable technique 
for detecting metals and metalloids in environmental samples. The total heavy metal content 
of the sample AC was performed by Atomic Absorption Spectrometry (AAS) Model AA 
240 Series. In order to determination the heavy metals such as mercury, arsenic, lead and 
cadmium concentrations in the test sample AC 
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 Sample Digestion 
                  Test sample AC digested with 1mol/L HCl for determination of arsenic and 
mercury. Similarly for the determination of lead and cadmium the sample were digested 
with 1mol/L of HNO3. Standard reparation  As & Hg- 100 ppm sample in 1mol/L HCl  Cd 
& Pb- 100 ppm sample in 1mol/L HNO3  
Standard reparation 
            As & Hg- 100 ppm sample in 1mol/L HCl 
            Cd & Pb- 100 ppm sample in 1mol/L HNO3  
 
MICROBIAL CONTAMINATION TEST BY POUR PLATE METHOD 
Objective  
             The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition rich 
medium it promotes the growth of the organism and after stipulated period of incubation the 
growth of the organism was identified by characteristic pattern of colonies. The colonies are 
referred to as Colony Forming Units (CFUs).   
Methodology 
           Test sample was admixed with sterile distilled water and the mixture were been used 
for the sterility evaluation. About 1ml of the test sample was inoculated in sterile petri dish 
to which about 15 mL of molten agar 45
o
C were added. Agar and sample were mixed 
thoroughly by tilting and swirling the dish. Agar was allowed to completely gel without 
disturbing it. (about 10 minutes). Plates were then inverted and incubated at 37
o
 C for 24-48 
hours. Grown colonies of organism was then counted and calculated for CFU. 
Observation 
          No growth was observed after incubation period, reveals the absence of specific 
pathogen 
Test for Specific Pathogen: 
Methodology 
                One part of the test sample was dissolved in 9 mL of sterile distilled water and the 
test sample was directly inoculated in to the specific pathogen medium (EMB, DCC, 
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Mannitol ,Cetrimide) by pour plate method. The plates were incubated at 37
o
C for 24 - 72h 
for observation. Presence of specific pathogen identified by their characteristic color with 
respect to pattern of colony formation in each differential media. 
Observation  
        No growth was observed after incubation period, reveals the absence of specific 
pathogen 
Analysis of Pesticides Organochlorine, Organophosphorus and Pyrethroids: 
Extraction  
About 10 g of test substance were extracted with 100 ml of acetone and followed by 
homogenization for brief period. Further filtration was allowed and subsequent addition of 
acetone to the test mixture. Heating of test sample was performed using a rotary evaporator 
at a temperature not exceeding 40ºC until the solvent has almost completely evaporated. To 
the residue add a few milliliters of toluene R and heat again until the acetone is completely 
removed. Resultant residue will be dissolved using toluene and filtered through membrane 
filter. 
 Aflatoxin Assay by TLC (B1,B2,G1,G2): 
Solvent 
          Standard samples was dissolved in a mixture of chloroform and acetonitrile (9.8 : 0.2) 
to obtain a solution having concentrations of 0.5 µg per ml each of aflatoxin B1 and 
aflatoxin G1 and 0.1 µg per ml each of aflatoxin B2 and aflatoxin G2.   
Test solution:  
         Concentration 1 µg per ml  
Procedure  
          Standard aflatoxin was applied on to the surface to pre coated TLC plate in the 
volume of 2.5 µL, 5 µL, 7.5 µL and 10 µL. Similarly the test sample was placed and Allow 
the spots to dry and develop the chromatogram in an unsaturated chamber containing a 
solvent system consisting of a mixture of chloroform, acetone and isopropyl alcohol (85 : 
10 : 5) until the solvent front has moved not less than 15 cm from the origin. Remove the 
plate from the developing chamber, mark the solvent from and allow the plate to air-dry. 
Locate the spots on the plate by examination under UV light at 365 nm.   
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4.2 Phytochemical analysis 
Test for Starch: 
2ml of extract was treated with weak dil.Iodine solution. 
Test For Reducing Sugar: 
5ml of Benedict's qualitative solution was taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the extract and again boil it for 2 minutes. The colour 
changes are noted. 
Test for the Alkaloids: 
a) 2ml of the extract was treated with 2ml of dil.potassium Iodide solution. 
b) 2ml of the extract was treated with 2ml of dil.picric acid. 
c) 2ml of the extract was treated with 2ml of dil.phosphotungstic acid. 
Test for Tannic Acid: 
2ml of extract was treated with 2ml of dil.ferric chloride solution. 
Test for AminoAcid: 
2 drops of the extract was placed on a filter paper and dried well. 20ml of Burette 
reagent is added. 
Test for Coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow colour. 
Test for Saponins:  
To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for glycosides- Borntrager’s Test: 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water 
bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of filtered 
hydrolysate, 3 ml of chloroform is added and shaken, chloroform layer is separated and 
10% ammonia solution is added to it. Pink colour indicates presence of glycosides. 
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Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added followed 
by addition of few drops of conc. Sulphuric acid. Appearance of yellow color indicates the 
presence of Flavonoids. 
Test for phenols:Lead acetate test:  
To the test sample; 3 ml of 10% lead acetate solution was added.  A bulky white 
precipitate indicated the presence of phenolic compounds. 
Test for steroids: 
To the test sample, 2ml of chloroform was added with few drops of conc. Sulphuric 
acid (3ml), and shaken well. The upper layer in the test tube was turns into red and 
sulphuric acid layer showed yellow with green fluorescence. It showed the presence of 
steroids. 
Triterpenoids: 
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from the 
sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
Test for Cyanins: 
Anthocyanin: 
To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min at 
100°C. Formation of bluish green colour indicates the presence of anthocyanin. 
 
4.3 BIOCHEMICAL ANALYSIS 
Biochemical Analysis of  Amukkara chooranam was done at the Biochemistry lab at 
National Institute of Siddha, Chennai by the method of Kolkate.  
Preparation of Extract: 
5ml of sample was taken in a 250ml clean beaker and added with 50ml of distilled 
water. Then it is boiled well for about 10 minutes. Then it is cooled and filtered in a 100ml 
volumetric flask and made up to 100ml with distilled water. This preparation is used for the 
qualitative analysis of acidic/basic radicals and biochemical constituents in it. 
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PROCEDURE: 
I. Test for Acid Radicals 
Test for Sulphate: 
2ml of the above prepared extract was taken in a test tube to this added 2ml of 4% 
dil ammonium oxalate solution 
Test for chloride: 
2ml of the above prepared extracts was added with 2ml of dil.HCl is added until the 
effervescence ceases off. 
Test for Phosphate: 
2ml of the extract were treated with 2ml of dil.ammoniummolybdate solution and 
2ml of con.HNo3. 
Test for carbonate: 
2ml of the extract was treated with 2ml of dil. magnesium sulphate solution. 
Test for Nitrate: 
1gm of the extract was heated with copper turning and concentrated H2So4 and 
viewed the test tube vertically down. 
II.Test for Basic radicals 
Test for lead: 
2ml of the extract was added with 2ml of dil.potassium iodine solution. 
Test for copper: 
One pinch (25mg) of extract was made into paste with con. HClin a watch glass and 
introduced into the non-luminuous part of the flame. 
Test for Aluminium: 
To the 2ml of extract dil.sodium hydroxide was added in 5 drops to excess. 
Test for Iron:  
a. To the 2ml of extract add 2ml of dil.ammonium solution  
b. To the 2ml of extract 2ml of thiocyanate solution and 2ml of con HNo3 is added. 
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Test for Zinc: 
To 2ml of the extract dil.sodium hydroxide solution was added in 5 drops to excess 
and dil.ammonium chloride was added.  
Test for Calcium: 
To 2ml of the extract was added with 2ml of 4% dil.ammonium oxalate solution 
Test for Magnesium: 
To 2ml of extract dil.sodium hydroxide solution was added in drops to excess. 
Test for Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent and excess of dil.sodium hydroxide 
solution are added. 
Test for Potassium: 
A pinch (25mg) of extract was treated off with 2ml of dil.sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate in 30% dil.glacial acetic acid. 
Test for Sodium: 
2 pinches (50mg) of the extract is made into paste by using HCl  and introduced into 
the blue flame of Bunsen burner. 
Test for Mercury: 
2ml of the extract was treated with 2ml of dil.sodium hydroxide solution. 
Test for Arsenic: 
2ml of the extract was treated with 2ml of dil.sodium hydroxide solution. 
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 4.4 Pharmacological actrivity 
In-vitro Anti-Inflammatory Activity by Protein (Albumin) denaturation Assay 
Albumin Denaturation Assay Procedure 
In-vitro anti-inflammatory activity AC was studied using albumin denaturation 
technique. The reaction mixture consisted of bovine serum albumin (5% aqueous solution) 
and test sample AC at varying concentration ranges from 100 to 500 µg/ml and standard 
Diclofenac sodium at the concentration of100 µg /ml of final volume. pH was adjusted by 
using a small amount of 1N Hydrochloric acid. The samples were incubated at 37°C for 20 
min and then heated at 57°C for 3 min. After cooling the sample, 2.5 ml of phosphate buffer 
solution was added into each test tube. Turbidity developed was measured 
spectrophotometrically at 660 nm, for control distilled water was used instead of test sample 
while product control tests lacked bovine serum albumin. The experiment was performed in 
triplicate. 
The Percentage protection from denaturation is calculated by using the formulae 
 
Preparation of Test and control 
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Absorbance of reaction mixture – Test Sample 
 
 
 
 
Absorbance of reaction mixture – Control and Standard 
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Clinical studies 
METHODOLOGY: 
 
STUDY TYPE       :    An open clinical trial 
STUDY PLACE    :   AYOTHIDASS PANDITHAR HOSPITAL (OPD & IPD),  
                                    NATIONAL INSTITUTE OF SIDDHA, 
                                    TAMBARAM SANATORIUM, 
                                  CHENNAI-47. 
STUDY PERIOD  :   24 Months 
NUMBER OF PATIENTS    :  30 Patients 
  
DRUG FORMULATION:  
 AMUKKARA  CHOORANAM (INTERNAL) 
 VETTIVER THYLAM (EXTERNAL)           
                 
INCLUSION CRITERIA: 
 Age: 5 – 12 years 
 Sex: Both male and female children. 
 Erythema 
 Thickness 
 Scaling 
 With or Without itching 
 Auspitz sign + 
 Candle crease sign + 
 Cracks followed by itching  
 Dryness of the skin 
 Willing to cooperate for taking photographs whenever required with his\her 
consent. 
 Patients who were willing to stay in IPD Ward for atleast 10 days or willing to 
attend OP Dept. as on required. 
 Patient‘s informant / Parent willing to sign the informed consent stating that he/she 
will consciously stick to the treatment during 14 days but can opt out of the trial of 
his / her own conscious discretion.  
100 
 
EXCLUSION CRITERIA: 
 Psoriatic arthritis 
 Evidences of  secondary infections in the lesions 
 Eczema  
 Psoriasis with evidence of .any other skin diseases  
 Fungal infestation 
 Systemic involvement 
 
WITHDRAWAL CRITERIA: 
 Exacerbation of symptoms and signs 
 If any adverse reactions and unwanted symptoms occurred during the drug 
trial. 
 Intolerance to the drug. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness.  
 
CLINICAL ASSESSMENT: 
To assess the improvement by PASI Score. 
 
CLINICAL ASSESSMENT 
 
                                                             PASI Calculation 
Patient name   
Date   
Plaque Characteristic Rating Score 
Body region and weighting factor 
Head 
Upper 
Limbs 
Trunk 
Lower 
Limbs 
Erythema 0 = None         
Thickness 
1 = Slight 
        
2 = Moderate 
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SIDDHA  ASSESSMENT: 
 
 Nilam 
 Kalam 
 Uyirthathukkal 
 Udal thathukkal     
 Envagai thervugal 
 Neerkuri 
 Neikkuri 
 
STUDY ENROLLMENT: 
 In this study, patients reporting at the NIS OPD were examined clinically for 
enrolling in the study based on inclusion and exclusion criteria.  
 The patients who were to be enrolled would be informed about the study, trial drug, 
possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
Scaling 
3 = Severe 
        4 = Very 
Severe 
 Totals A1= A2= A3= A4= 
Weighting Factor A1x0.1=B1 A2x0.2=B2 A3x0.3=B3 A4x0.4=B4 
Surface area totals B1= B2= B3= B4= 
  
Degree of 
involvement as  
% for each body 
region  
affected (score each  
region between 0 and 
6) 
0 = None 
    
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Surface area totals x % involvement 
totals 
Sum Scores above = 
B1xscore=
C1 
B2xscore=
C2 
B3xscore=
C3 
B4xscore=
C4 
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 After ascertaining the patient‘s informant willingness, informed consent (Form II ) 
was obtained in writing from their parents in the consent form. 
 All these patients were given Investigators phone number so as to report easily if 
any complications arise. 
 Complete clinical history, complaints and duration, examination findings-- all would 
be recorded in the prescribed Proforma in the history and clinical assessment forms 
separately. Screening Form- I was filled up. Form III was used for recording the 
patient‘s history and clinical examination of symptoms and signs respectively. 
  Patient were advised to take the trial drug and appropriate dietary advice 
 ( Form-IV) would be given according to the patient‘s perfect understanding 
CONDUCT OF THE STUDY:  
 The trial drug ―AMUKKARA CHOORANAM (INTERNAL) AND VETTIVER 
THYLAM (EXTERNAL)‖ was given for 48 days and the Patients were advised to 
visit the OP once in 7 days. 
 At each clinical visit clinical assessment was done and prognosis was noted. 
 For IP patients the drug was given daily and prognosis was noted.  
 For IP patients who were not in a situation to stay in the hospital for a long time they 
were advised to attend the OPD for further follow up. 
 Siddha investigations like Neerkuri and Neikuri were carried over. After the end of 
the treatment the patient were advised to visit the OPD for another 1 month for 
follow up.  
 If any trial patients who failed to collect the trial drug on the prescribed day but want 
to continue in the trial from the next day or two, be he/she was allowed, but 
defaulters more than three days was not  allowed to continue and be withdrawn from 
the study with a fresh case being included 
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DATA MANAGEMENT:  
 After enrolling the patient in the study, a separate file for each patient was opened 
and all forms were filed in the file. Study No. and Patient No. were entered on the 
top of file for easy identification. 
 Whenever study patient visits OPD during the study period, the respective patient 
file was taken and necessary recordings were made at the assessment form or other 
suitable form. 
 The Data recordings in all forms was monitored and scrutinized by HOD, Dept. of 
Kuzhandhai Maruthuvam. 
 Data analysis was done with the help of senior research officer (Statistics) of NIS. 
 
ADVERSE EFFECT / SERIOUS EFFECT MANAGEMENT: 
If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and proper management will be given in OPD of National Institute 
of Siddha. The details of adverse reactions will be recorded in prescribed 
Pharmacovigilance form and the same will be reported to Regional Pharmacovigilance 
center . 
ETHICAL ISSUES:                     
 No other external or internal medicines was used.  
 The data collected from the patient‘s informant will be recorded. The patient‘s 
informant  will be informed about the diagnosis, treatment and follow-up.  
 After the consent of the patient‘s informant (through consent form), patient was 
enrolled in the study.  
 Informed consent was obtained from the patient‘s informant explaining in the 
understandable language to the patient‘s informant. 
 Treatment would be provided free of cost. 
 In conditions of treatment failure, adverse reactions, patients were given  alternative 
treatment at the National Institute of Siddha with full care.    
 
7. OUT COME: 
 Efficacy of the trial drug is measured by PASI Score. 
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PASI score  
A PASI score is a tool used to measure the severity and extent of psoriasis (Psoriasis 
Area and Severity Index).  
Intensity  
A representative area of psoriasis is selected for each body region. The intensity of 
redness, thickness and scaling of the psoriasis is assessed as none (0), mild (1), moderate 
(2), severe (3) or very severe (4).  
Psoriasis: severity scoring  
Intensi
ty  
Absent  Mild  Moderate  Severe  Very severe  
Redness  
 
Score 0  
 
Score 1  
 
Score 2  
 
Score 3  
 
Score 4  
Thickness  
 
Score 0  
 
Score 1  
 
Score 2  
 
Score 3  
 
Score 4  
Scaling  
 
Score 0  
 
Score 1  
 
Score 2  
 
Score 3  
 
Score 4  
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8. DATA COLLECTION FORMS:- 
 
 FORM I -   SCREENING & SELECTION PROFORMA 
 FORM II a -    CONSENT FORM 
 FORM II b -  ASSENT FORM 
 FORM III     -   CASE RECORD FORM 
 FORM IV -  DIETARY FORM  
 FORM V       -  INFORMATION SHEET.  
  FORM VI     -  DRUG COMPLAINCE 
 FORM VII    -  WITHDRAWAL FORM 
 FORM VIII     -  ADVERSE EFFECT  
 FORM IX      -  PHARMOCOVIGILANCE 
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OBSERVATION AND RESULTS 
 
4.1 Physico chemical anakysis: 
 
Organoleptic Character 
 
Table 5.1 
 
State Solid 
Appearance Pale Brownish 
Nature Moderately Coarse powder 
Odour Strongly Aromatic  
 
Fig 5.1 Amukkara Chooranam 
 
 
 
Physicochemical Character of Amukkara Chooranam 
         Table 5.2 
S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 8.3  ±  3.55 
2.  Total Ash (%)  2.64  ±  0.25 
3.  Acid insoluble Ash (%) 1.60  ±  0.03 
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4.  Water Soluble Ash (%) 11.87  ±  2.99 
5.  Alcohol Soluble Extractive (%) 36.9  ±  1.38 
6.  Water soluble Extractive (%) 36.87 ±  1.72 
       7. PH   5 
 
PARTICLE SIZE DETERMINATION 
Microscopic observation of the particle size analysis reveals that the average particle 
size of the sample AC was found to be 107.4± 32.18 µm further the sample AC has particle 
with the size range of lowest 46.63 µm to highest 163.3 µm  
 
Fig 5.2 
 
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY : 
         HPTLC finger printing analysis of the sample AC reveals the presence of seven 
prominent peaks corresponds to presence of seven versatile phytocomponents present with 
in it. Rf value of the peaks ranges from 0.22 to 0.76.  Further the peak 2 occupies the major 
percentage of area of 26.58 % which denotes the abundant existence of such compound. 
Followed by this peak 4 and 7 occupies the percentage area of 25.80 and 14.06 % 
respectively. 
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HPTLC finger printing of Sample AC 
 
 
                                           Fig 5.3 HPTLC finger printing 
HPTLC peak table: 
Table 5.3 
 
Fluorescence analysis in dried powder  
Sample ACwas subjected to fluorescence analysis under visible light and UV – 
Light at 365 nm under closed circuit cabinet. Each fluorescence characteristic of the treated 
sample was observed under ordinary light and then under UV light of wave lengths 365 nm. 
The drug was treated with acids viz., Conc. HCl, Conc. H2SO4, Conc. HNO3 and glacial 
acetic acid. The drug was treated with alkaline solutions viz., aqueous NaOHand ferric 
chloride. They were subjected to fluorescence analysis in visible light and in short UV- light 
(254 nm) and long UV- light (365 nm). 
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Fig 5.4 Visible light 
 
Fig 5.5 Short UV- light (254 nm) 
 
Fig 5.6 Long UV- light (365 nm) 
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S.No Experiment Visible light Short  
UV – Light 
254 nm 
Long  
UV – Light 
365 nm 
1.  Sample + Conc. Hcl Pale Yellow Greenish yellow Brownish 
2.  Sample + Conc. Sulphuric 
Acid 
Greenish Black Blackish Reddish black 
3.  Sample + Conc. Nitric acid Creamy yellow Fluorescent green Reddish brown 
4.  Sample + Sodium hydroxide 
in water 
Milky White Fluorescent yellow Fluorescent 
orange 
5.  Sample + Ferric chloride Brownish orange Greenish black Reddish 
6.  Sample + glacial acetic acid Pale Yellow Lime Yellow Fluorescent 
yellow 
7.  Sample + Water Milky White yellow Fluorescent 
yellow 
 
HEAVY/TOXIC METAL ANALYSIS BY AAS: 
Report and Inference  
Results of the present investigation has clearly shows that the sample AC has no 
traces of heavy metal lead. Further the results shows the presence of Mercury, Arsenic and 
cadmium at 0.0008, 0.0004 and 0.001 ppm level.  
        The reported heavy metals such as mercury, arsenic and cadmium seems very low 
when compared to the allowed recommended limit  
Table 5.4  for heavy metal analysis 
Name of the Heavy 
Metal 
Absorption Max 
Max 
Result Analysis Maximum Limit 
Mercury 253.7 nm 0.0008 ppm 1 ppm 
Lead 217.0 nm BDL 10 ppm 
Arsenic 193.7 nm 0.0004 ppm 3 ppm 
Cadmium 228.8 nm 0.001 ppm 0.3 ppm 
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MICROBIAL CONTAMINATION TEST BY POUR PLATE METHOD: 
No growth / colonies were observed in any of the plates inoculated with the test sample. 
Table 5.5 
Test Result Specification As per AYUSH/WHO 
Total Bacterial Count Absent NMT 10
5
CFU/g As per AYUSH specification 
Total Fungal Count Absent NMT 10
3
CFU/g 
 
 
Fig 5.7 Microbial contamination test by Pour plate method 
 
TEST FOR SPECIFIC PATHOGEN 
Result 
No growth / colonies were observed in any of the plates inoculated with the test sample. 
Table 5.5 
Organism Specification Result Method 
E-coli Absent Absent As per AYUSH specification 
Salmonella Absent Absent 
Staphylococcus Aureus Absent Absent 
Pseudomonas Aeruginosa Absent Absent 
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Fig 5.8    Culture plate with E-coli and Salmonella specific medium 
 
Fig 5.9 Culture plate with Staphylococcus Aureus specific medium 
 
Fig 5.10  Culture plate with Pseudomonas Aeruginosa specific medium 
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ANALYSIS OF PESTICIDES ORGANOCHLORINE, ORGANOPHOSPHORUS 
AND PYRETHROIDS: 
Result:  
Table 5.7 
Pesticide Residue 
Sample AC 
AYUSH Limit 
(mg/kg) I.Organo Chlorine 
Pesticides 
Alpha BHC BQL 0.1mg/kg 
Beta BHC BQL 0.1mg/kg 
Gamma BHC BQL 0.1mg/kg 
Delta BHC BQL 0.1mg/kg 
DDT BQL 1mg/kg 
Endosulphan BQL 3mg/kg 
II.Organo Phosphorus 
Pesticides 
 
 
Malathion BQL 1mg/kg 
Chlorpyriphos BQL 0.2 mg/kg 
Dichlorovos BQL 1mg/kg 
III.Pyrethroid 
 
 
Cypermethrin BQL 1mg/kg 
 
       The results showed that there were no traces of pesticides residues such as Organo 
chlorine, Organo phosphorus and pyrethroids in the sample AC. It further shows the above 
mentioned residues were not been detected in the sample AC provided for analysis. 
AFLATOXIN ASSAY BY TLC (B1,B2,G1,G2): 
Table 5.8 
Aflatoxin Sample AC AYUSH Specification 
Limit 
B1 Not Detected – Absent 0.5 ppm 
B2 Not Detected – Absent 0.1 ppm 
G1 Not Detected – Absent 0.5 ppm 
G2 Not Detected – Absent 0.1 ppm 
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Result:  
           The results shown that there was no spots were been identified in the test sample 
loaded TLC plated when compare to the standard indicates that he sample were free from 
Aflatoxin B1, Aflatoxin B2, Aflatoxin G1, Aflatoxin G2. 
 
4.3 BIOCHEMICAL ANALYSIS OF AMUKKARA CHOORANAM: 
I Results of Acid radical studies: 
Table 5.9 
S.NO Parameter Observation Result 
1 Test for Sulphate Cloudy appearance        
Present 
Positive 
2 Test for Chloride              -    Negative 
3 Test For Phosphate             - Negative 
4 Test For Carbonate   Cloudy appearance         
Present 
Positive 
5 Test For Nitrate  
- 
Negative 
6 Test for Sulphide  
- 
Negative 
7 Test For Fluoride &oxalate 
 
 
- 
Negative 
8 Test For Nitrite 
 
- 
 
Negative 
9 Test For Borax 
 
- Negative 
 
Interpretation 
  The acidic radicals test shows the presence of Sulphate and Carbonate. 
II Results of basic radicals studies: 
Table 5.10 
S.NO Parameter Observation Result 
1 Test for Lead - Negative 
2 Test for Copper - Negative 
3 Test For Aluminium  - Negative 
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4 Test For Iron Mild red colour appear Positive 
5 Test For Zinc White precipitate is formed Positive 
6 Test for Calcium Cloudy appearance and white 
precipitate  present 
Positive 
7 Test For Magnesium  White precipite is obtained. Positive 
8 Test For Ammonium Brown colour appear Positive 
9 Test For Potassium - Negative 
10  Test For Sodium - Negative 
11 Test For Mercury - Negative 
12 Test For Arsenic - Negative 
 
Interpretation 
 The basic radical test shows the presence of Iron, Zinc,Calcium,Ammonium, 
Magnesium and absence of heavy metals such as lead, arsenic and mercury. 
  
Fig 5.11 Test for Alkoloid                                                   fig 5.12 Test for Flavonoid 
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Fig 5.13 Test for Glycosides                                                    fig 5.14 Test for Steroids 
                                  
Fig 5.15 Test for Triterpenoids    Fig .5.16 Test for Coumarins 
                                                   
Fig 5.17 Test for  Phenol                                              Fig 5.18 Test for Tannin 
117 
 
                  
Fig 5.19 Test for Protein    fig 5.20 Test for Saponin 
                   
Fig 5.21 Test for Carbohydrate          fig 5.22  Test for Anthocyanin 
4.4 PHARMACOLOGICAL  ACTIVITY 
In-vitro Anti-Inflammatory Activity by Protein (Albumin) denaturation Assay 
      Table 5.11 
Concentration in µg/ml 
Percentage Inhibition of Protein 
Denaturation 
AC 100 17.02  ± 7.30 
AC 200 32.06  ± 4.26 
AC 300 38.34  ± 2.95 
AC 400 51.52  ± 0.83 
AC 500 70.89  ± 5.28 
Diclofenac sodium                
(100 µg) 94.74  ± 4.25 
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Result Analysis 
The result obtained from the present clearly indicates that the test drug AC was 
effective in inhibiting heat induced albumin denaturation. Maximum percentage inhibition 
of about 70.89 % was observed at 500 μg/ml when compareD to that of the Diclofenac 
sodium, a standard anti-inflammatory agent with the maximum inhibition 94.74 % at the 
concentration of 100 μg/ml. 
Conclusion 
From the result of the study it was concluded that the test drug AC possess 
significant anti-inflammatory property in protein denaturation assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119 
 
CLINICAL STUDIES: 
 
DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING  
TO  AGE  
                          Table 5.12 
 
 
 
      
 
 
 
 
 
Fig  5.23 
Inference: 
          Out of 30 patients, 40% of cases were between 11-12 years, 36 % of cases were 
between 9-10 years,     17 % of cases were within 7 – 8 years , 7% of cases were within 5 – 
6 years. The highest incidence was seen in the age group of 11-12 years.  
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AGE
5 to 6 yrs
7 to 8 yrs
9 to 10 yrs
11 to 12 yrs
S.NO Age No. Of. Cases Percentage 
1 5-6 2 7 % 
2 7-8 5 17 % 
3 9-10 11 36 % 
4 11-12 12 40 % 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
SEX DISTRIBUTION 
                  Table 5.13 
 
S.No Sex No.Of.Cases Percentage 
1 Male Child 14 47 % 
2 Female Child 16 53% 
 
 
Fig 5.24 
 Inference 
           Out of 30 patients 47 % were male children and 53% were female children. 
According to this study both sexes were more or less equally affected which shows 
kaalanjaga padai is does not have any predominant on sex.  
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
SOCIO ECONOMICAL SYSTEM 
              Table 5.14 
S.No Socio economical System No.Of.Cases Percentage 
1 Upper 4 13 % 
2 Upper Middle 14 47% 
3 Middle Lower Middle 10 33 % 
4 Lower Upper Middle 2 7 % 
 
 
Fig 5. 25 
Inference 
About 13% patients belongs to upper class, 47% patients belongs to upper middle 
class, 33% patients belongs to Lower middle class and 7% patients of lower class. The 
highest incidence occurred in Upper middle income group.  
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
RELIGION 
           Table 5.15 
S.No Religion No.Of.Cases Percentage 
1 Hindu 27 90 % 
2 Christian 2 7 % 
3 Muslim 1 3 % 
 
 
Fig  5.26 
Inference 
About 90% patients were Hindu, 7% patients were Christian, 3% patients were 
Muslim. 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
THINAI: 
                  Table 5.16 
S.No Thinai No.Of.Cases Percentage 
1 Kurinji 1 3 % 
2 Mullai 0 0 % 
3 Marutham 11 37% 
4 Neithal 18 60 % 
5 Paalai 0  0 % 
          
 
Fig 5.27 
Inference 
Among 30 patients, 60% were from Neithal land, 37 % from Marutham land, 0 % 
from Mullai land, and 3% from Kurinji land. Since this study was carried out in Chennai, 
the highest incidence of people seeking  treatment were from the sourrounding of Chennai 
and hence highest incidence was noted in Neithal nilam. 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
PARUVAKAALAM 
            Table 5.17 
S.No ParuvaKaalam No.Of.Cases Percentage 
1 KaarKaalam 2 7 % 
2 KoothirKaalam 4 13.33 % 
3 Munpani 8 26.66 % 
4 Pinpani 16 53.33 % 
5 Ilavenil 0 0 % 
6 Muthuvenil 2 6.66% 
 
 
Fig 5.28 
Inference 
Among 30 patients, 53.33 % were treated during Pinpani kaalam, 26.66 % in 
Munpani kaalam, 7% in Kaar kaalam ,13.33% were in Koothir kaalam, 6.66 % were trated 
in  muthuvenil kaalam. The highest incidence was noted in Pinpanikaalam. 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
DURATION OF  ILLNESS 
           Table 5.18 
S.No Duration of illness No.Of.Cases Percentage 
1 1 month – 2 years 18 60 % 
2 3 – 5 years 8 26 % 
3 6 – 8 years 2 7% 
4 9 – 10 years 2 7 % 
 
 
 
Fig 5.29 
Inference 
         Among 30 patients 60% of cases were suffering within a duration of 1 month- 2 years, 
26% of cases suffering for a duration of 3-5 years, 7% were having duration of 6 – 8 years ,   
7 % of cases has the duration of 9- 10 years. 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
FOOD HABITS 
              Table 5.19 
S.No Food Habits No.Of.Cases Percentage 
1 Vegtarian 2 7 % 
2 Non – Vegtarian 28 93 % 
 
 
Fig 5.30 
 
Inference 
       According to diet, Vegetarian 7%, Non vegetarian 93% were noted. The highest 
incidence was seen in Non-Vegetarian. But the disease  has no influence on diet. 
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UYIRTHATHUKKAL 
DISTRIBUTION OF CHILDREN WITH KAALANAJAGA PADAI ACCORDING 
TO DERANGEMENT OF VATHAM: 
            Table 5.20 
S.No Vaatham No.Of.Cases Percentage 
1 Pranan 3 10 % 
2 Abanan 0 0 % 
3 Viyanan 30 100 % 
4 Udhanan 0 0 
5 Samanan 30 100 % 
6 Naagan 0 0 % 
7 Koorman 0 0 % 
8 Kirukaran 0 0 % 
9 Devathathan 0  0 % 
10 Thananjeyan  -  - 
 
 
Fig 5.31 
Inference 
        According to vatham, derangement of Pranan was noted in 10% of cases , Viyanan and 
Samanan was affected in 100% of childrens. 
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DISTRIBUTION OF CHILDREN WITH KAALANAJAGA PADAI ACCORDING 
TO DERANGEMENT OF PITHAM:  
 
        Table 5.21 
 S.No Pitham 
 
No.Of.Cases Percentage 
1  
Anarpitham 
0  0 % 
2  
Ranjagapitham 
0 0% 
3  
Sadhagam 
30  100 % 
4  
Prasagam 
30 100 % 
5  
Alosagam 
0  0 % 
 
 
Fig 5.32 
Inference 
According to Pitham, derangement of prasagapitham and saathaga pitham was noted 
in  100% of cases due to erythema and  scaly patches . 
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DISTRIBUTION OF CHILDREN WITH KAALANAJAGA PADAI ACCORDING 
TO DERANGEMENT OF EZHU UDARKATTUGAL 
           Table 5.22 
S.No UdarThathukkal No.Of.Cases Percentage 
1 Saaram 30 100 % 
2 Senneer 30 100 % 
3 Oon 0 0% 
4 Kozhuppu 0 0 % 
5 Enbu 0 0 % 
6 Moolai 0 0 % 
7 Sukkilam / Suronitham 0 0% 
 
 
Fig 5.33 
Inference 
According to the study, Saram was affected in 100% of cases due to presence of 
fatigue, Senneer was affected in 100% due to itching,Oon was affected in 100%due to the 
presence of  Scaling and erythematous lesion. 
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DISTRIBUTION OF CHILDREN WITH KAALANAJAGA PADAI ACCORDING 
TO DERANGEMENT OF ENN VAGAI THERVUGAL: 
                  Table 5.23 
S.No EnvagaiThervu No.Of.Cases Percentage 
1 Naa 0 0 %  
2 Niram 30 100 % 
3 Mozhi 0 0 % 
4 Vizhi 0 0 % 
5 Malam 0 0% 
6 Moothiram 0 0 % 
7 Naadi 0 0 % 
8 Sparisam 30 100 % 
 
 
Fig 5.34 
Inference 
               Out of 30 cases, 100% of the cases were affected by Niram.100% of cases affected 
by sparisam due to scaling and erythematous lesion present in the skin.  
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
OBSERVATION OF NAADI: 
       Table 5.25 
 
 
Fig 5.35 
Inference: 
 Out of 30 cases 40 % of the cases were noted to have vaatha pitha naadi , 50% of the 
cases has pithavaatha  naadi, 10 % of the cases has kabapitha  naadi 
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S.No Naadi No.Of.Cases Percentage 
1 Vaathapitham 12 40  % 
2 Pithavaatham 15 50 % 
3 Kabapitham 3 10% 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
OBSERVATION OF NEERKURI ANALYSIS: 
Table 5.26 
 
 
Fig 5.36 
   Inference: 
 Out of 30 cases 43.33% of the cases has vaatha neer,33.33% of the cases has 
pithaneer , 23.33% of the cases has kabaneer. 
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S.No Neerkuri No.Of.Cases Percentage 
1 Vaatha Neer 13 43.33 % 
2 Pitha Neer 10 33.33 % 
3 Kaba Neer 7 23.33 % 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
OBSERVATION OF NEIKURI ANALYSIS: 
                Table 5.27 
S.No Neikuri No.of.Cases Percentage 
1 Vaatham 7 23.33 % 
2 Pitham 5 16.66 % 
3 Kabam 18 60 %s 
 
          
Fig 5.37 
Inference: 
           Out of 30 cases , 60% of the cases has kabaneer , 23.33 % of the cases has 
vaathaneer , 16.66 % of the cases has pithaneer. 
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DISTRIBUTION OF CHILDREN WITH KAALANJAGA PADAI ACCORDING TO 
OBSERVATION OF SITE OF LESION: 
     Table 5.28 
S.No Site of Lesions No.of.cases Percentage 
1 Head and Face 6 20 % 
2 Upper Limb 14 46.66  % 
3 Palm 3 10% 
4 Trunk 12 40 % 
5 Lower Limb 16 53.33 % 
6 Feet 11 36.66 % 
 
 
Fig  5.38 
Inference: 
 Out of 30 cases , 20% of the cases has lesion in head and face, 47% of the cases has 
lesion in upper limb , 10% of the cases has lesion in palm, 40% of the cases has lesion in 
trunk, 53% of the cases has lesion in  lower limb, 36.66% of the cases has lesion in face.  
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CASE REPORT OF CHILDREN BASED ON PASI SCORE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GOOD            MODERATE   MILD 
S.No OP / IP No Age / Sex BT  AT PASI Result 
1 I 87705 11 / FCH 45.4 1.4 PASI 75 GOOD 
2 J 17659 5 .5 /MCH 36.7 2 PASI 75 GOOD 
3 J 52223 9 / MCH 37.5 0 PASI 75 GOOD 
4 J 69168 7 / MCH 25.5 1.2 PASI 75 GOOD 
5 J 26164 5 / FCH 7.2  0.9 PASI 75 GOOD 
6 J 59864  10 / MCH 35.7 0.9 PASI 75 GOOD 
7 H 66710 12 / FCH 15.6 2.4 PPPASI 50 MODERATE 
8 J 81757 10 / FCH 18.2 3.8 PASI 50 MODERATE 
9 G 91777 10 / MCH 20 8 PPPASI 50 MODERATE 
10 J 82013 9 / FCH 6 2.4 PPPASI 25 MILD 
11 H 98294 9 / MCH 32 6 PPPASI 50 MODERATE 
12 J 91116 10 / FCH 48.6 0 PASI 75 GOOD 
13 H 52991 12 / FCH 6 1.2 PASI 50 MODERATE 
14 J 02758 8 / FCH 6 0 PASI 75 GOOD 
15 J 72808 12 / FCH 28.8 0.6 PPPASI 75 GOOD 
16 I 72038 12 / MCH 2.4 0.8 PASI 75 GOOD 
17 J 93536 7 / FCH 4.8 0.6 PPPASI 50 MODERATE 
18 J 98283 12 / MCH 3.2 1.6 PASI 50 MODERATE 
19 K 06891 9 / FCH 57 18.8 PASI 25 MILD 
20 K 11158 12 / MCH 65.8 0 PASI 75 GOOD 
21 K 12642 11 / MCH 21.6 0 PASI 75 GOOD 
22 I 86836 11 / MCH 4.8 0.6 PPPASI 50 MODERATE 
23 H 96207 10 / FCH 5.4 3.6 PASI 25 MILD 
24 K 15559 12 / FCH 18 2.4 PPPASI 50 MODERATE 
25 H 11608 12 / FCH 15 1.2 PPPASI 50 MODERATE 
26 K 17972 9 / MCH 21.6 0 PASI 75 GOOD 
27 G 72983 7 / FCH 1.6 0.4 PASI 75 GOOD 
28 J 85973 8 / FCH 9 7.2 PPPASI 25 MILD 
29 K 13112 11 / MCH 13.2 0 PPPASI 75 GOOD 
30 E 006153 9 / MCH 7.2 3.6 PPPASI25 MILD 
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Images of chilfrens Before and After treatment 
                           Case : 1     Before treatment           
 
 
 
 
 
 
 
 
 
 
     After treatment   
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Case  :  2   Before Treatment 
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Case  :  3  Before Treatment 
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              Case   :  3       After Treatment 
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Case 4  Before treatment 
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                                                               Case 4 After treatment 
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Case 5    Before treatment 
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Case 5 After treatment 
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                                             Case 6 Before and After treatment 
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Case 7 Before and After treatment 
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Case 8 Before And After Treatment 
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                                                   Case 9 Before and After treatment 
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                                                  Case 10 Before and After Treatment 
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STATISTICAL ANALYSIS: 
 All collected data were entered into MS Excel software using different columns as 
variables and rows as patients, SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical 
significance. Paired ‗t‘  test was performed for determining the significance between before 
and after treatment. In my study statistical analysis was done for PASI score. 
Paired Sample Statistics: 
PASI Score: 
Distribution of Mean and Standard Deviation of before and after treatment is as follows. 
PASI Score Mean ± Standard Deviation  t Value p Value 
Before treatment 20.66 ± 17.36  
5.95 
 
P < 0.0001 After treatment 2.39 ±3.75  
 
 The Mean Standard Deviation of PASI Score before and after treatment was 20.66 ± 
17.36 and 2.39 ± 3.7 respectively which is statistically significant (p < 0.0001).  
The analysis reveals that there is 88% reduction in erythema, scales and thickening of skin. 
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            DISCUSSION 
 
            `“KALANJAGA PADAI” is one among the skin disease affecting the age group           
5 – 12 years as encountered in the Siddha maruthuvam Sirappu. Kalanjaga padai more or 
less resembles Psoriasis in morden literature.The disease is characterised by Erythema, 
Thickening of skin , Scaling , Itchying and  pin- point bleeding  
In the present study, thirty cases were treated in the outpatient department, according 
to clinical features mentioned in textbook of Siddha maruthuvam Sirappu. The choosen 
drug Amukkara chooranam is indicated for  Kuttam (Kalanjaga padai is one of the variety 
of skin disease which comes under kuttam) and hence this trial drug is selected for treating 
the children with Kalanjaga padai. The diagnosis is confirmed based on clinical feautures 
and treated with the drug ―AMUKKARA CHOORANAM‖ and the prognosis is clearly 
observed. 
The study is conducted after being approved by IEC of NIS, vide Approval No: 
NIS/IEC/2016/11-17/14.10.2016.The trial is registered in Clinical trial Registry of India with 
Reg.No CTRI/2017/06/008935.The Authentication of ingredients of the trial drug was 
obtained from Medicinal Botanist Dr.D.Aravind,MD(S),MSc., National Institute of Siddha, 
Chennai. 
The trial drugs were prepared by the author in the Gunapadam practical laboratory 
of National Institute of Siddha, under the guidance and supervision of the guide. The trial 
drug was prepared by the standard operating procedure as mentioned in the protocol. 
Physicochemical analysis was done as a preliminary evaluation the trial drug 
Amukkara chooranam. Loss on drying (LOD) is a method of measuring the amount of 
water and volatile matters in a sample when the sample is dried. Low moisture content is 
always desirable for higher stability of drugs. In Amukkara chooranam, the loss on drying at 
105
o
C was found to be 8.3±3.55. So the determination of moisture content shows the good 
stability of the drug Amukkara chooranam.    
The total Ash values are helpful in determining the quality and purity of drugs, 
especially in powder form. The total Ash value in Amukkara chooranam was found to be 
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2.64±0.25. The minimal level of total ash shows the less inorganic residue and purity of the 
drug Amukkara chooranam.  
The extractive values help to indicate the nature of chemical constituents present in 
the drug. The water soluble substance is polar in nature and the alcohol has the ability to 
dissolve non-polar substance.The water soluble extract value of Amukkara chooranam is 
11.8±2.99 % and the Alcohol soluble extractive is 36.9±1.38%. It shows the possibility of 
water soluble constituents such as sugars, plant acids, mucilage and alcohol soluble 
substance such as tannins, resin sand alkaloids to be present in the drug.  
Strongly Acidic nature of the drug can cause harmful effects to the body, so the 
screening for the pH is important for drugs. It represents the chemical nature of the drug and 
the site of absorption of non-polar drug. The pH of Amukkara chooranam is found to be 5, 
that is weekly acidic and safe in pH. The weekly acidic drugs are rapidly absorbed from 
stomach. So the drug Amukkara chooranam can act rapidly on oral administration. 
 In HPTLC, Rf value of the peaks ranges from 0.22 to 0.76.  Further the peak 2 
occupies the major percentage of area of 26.8 % which denotes the abundant existence of 
such compound. Followed by this peak 4 and 7 occupies the percentage area of 2.80 and 
14.06% respectively. 
 In heavy metals analysis mercury was not detected and lead, arsenic, cadmium were 
present within the permissible limit. 
 Aflatoxin like B2, G1, G2were not detected except B1 which was within the 
permissible limit. 
Biochemical analysis 
The Bio chemical analysis of trial medicine showed the presence of Sulphate, 
Carbonate, Iron, Zinc, Calcium, Ammonium and Magnesium.  
Phytochemicals such as Starch, Sugar, Alkaloids, Tannic acid, flavonoids, steroids, 
triterpenoids, coumarin, saponins and phenol are present in the trial drug 
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Pharmacological activity 
               The anti-inflammatory activity of the trial drug AMUKKARA CHOORANAM  
was done at Noble Research Solutions, Sathyabama University, Chennai. In-vitro Anti-
inflammatory activity of AMUKKARA CHOORANAM was performed by protein 
(Albumin) denaturation method. The result obtained from the present study clearly indicates 
that the test drug was effective in inhibiting heat induced albumin denaturation. Maximum 
percentage inhibition of about 70.89% was observed at 500 μg/ml when compared to that of 
the Diclofenac sodium, a standard anti-inflammatory agent with the maximum inhibition of 
94.74 % at the concentration of 100μg/ml. 
Clinical study: 
            In clinical studies the patients were recruited for the trial based on inclusion and 
exclusion criteria and after getting the consent from the patient. 30 patients were included in 
this study. The 30 patients were treated in OPD of Ayothidoss Pandithar Hospital of 
National Institute of Siddha.Separate proforma was maintained for every patient. Progress 
chart was also maintained to monitor the clinical signs and symptoms of the disease.  
The treatment was aimed at normalizing the deranged thodams and providing relief 
from symptoms. Before treatment the patients were advised to adapt lifestyle modifications 
such as oil bath weekly once and to follow good dietary regimen. 
Children with small sized lesion (i.e) lesion over a small area was also selected for 
the study owing to the prolonged duration of lesion for 2- 4 years.The trial drug exhibits a 
tremendous results in this condition also which proves that this drugs are very efficatious in 
treating children with long standing psoriasis. 
The patients were treated with trial drug AMUKKARA CHOORANAM for 45 days. 
Patients were instructed to take the medicines regularly and advised to follow pathiyam. 
Patients were asked to visit the hospital regularly once in every 7 days for collecting the 
trial medicine and  assessment. After completion of the study, the patients were advised to 
visit the Out-Patient ward of Department of Kuzhanthai Maruthuvam for 1 month for 
follow-up. The results observed during the study period were discussed  below.   
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Clinical review 
             Out of 30 patients, 40% of cases were between 11-12 years, 36 % of cases were 
between 9-10 years,     17 % of cases were within 7 – 8 years , 7% of cases were within 5 – 
6 years. The highest incidence was seen in the age group of 11-12 years.  
           Out of 30 patients 47 % were male children and 53% were female children. 
According to this study both sexes were more or less equally affected which shows 
kaalanjaga padai is does not have any predominant on sex.  
About 13% patients belongs to upper class, 47% patients belongs to upper middle 
class, 33% patients belongs to Lower middle class and 7% patients of lower class. The 
highest incidence occurred in Upper middle income group.  
About 90% patients were Hindu, 7% patients were Christian, 3% patients were 
Muslim. 
Among 30 patients, 60% were from Neithal land, 37 % from Marutham land, 0 % 
from Mullai land, and 3% from Kurinji land. Since this study was carried out in Chennai, 
the highest incidence of people seaking  treatment were from the sourrounding of Chennai 
and hence  highest incidence was noted in Neithal nilam. 
Among 30 patients, 53.33 % were traeted in Pinpani kaalam, 26.66 % were treated 
in Munpani kaalam, 7% in Kaar kaalam ,13.33% were from Koothir kaalam, 6.66 % were 
treated in muthuvenil kaalam. The highest incidence was noted in Pinpanikaalam. 
         Among 30 patients 60% of cases were suffering with a duration of 1 month- 2 years, 
26% of cases suffering for with duration of 3-5 years, 7% were having duration of 6 – 8 
years ,   7 % of cases has the duration of 9- 10 years. 
       According to diet, Vegetarian 7%, Non vegetarian 93% were noted. The highest 
incidence was seen in Non-Vegetarian. But the disease  has no influence on diet. 
According to vatham, derangement of Pranan was noted in 10% cases, Viyanan and 
Samaanan was affected 100% of childrens . 
According to Pitham, derangement of prasagapitham and Saathagapitham was noted 
in  100% cases due to erythematous and scaly patches . 
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According to the study, Saram was affected in 100% of cases due to presence of 
fatigue, Senneer was affected in 100% due to the presence of itching,Oon was affected 
100% of cases due to the prsecnce of scaling and erythematous lesion.  
            Out of 30 cases, 100% of the cases were affected by Niram.100% of cases affected 
by sparisam due to scaling and erythematous lesion present in the skin.  
Out of 30 cases 40 % of the cases were noted to have vaatha pitha naadi , 50% of the 
cases has pithavaatha  naadi, 10 % of the cases has kabapitha  naadi. 
Out of 30 cases 43.33% of the cases has vaatha neer,33.33% of the cases has 
pithaneer , 23.33% of the cases has kabaneer. 
Out of 30 cases , 60% of the cases has kabaneer , 23.33 % of the cases has 
vaathaneer , 16.66 % of the cases has pithaneer 
          Out of 30 cases , 20% of the cases has lesion in head and face, 47% of the cases has 
lesion in upper limb , 10% of the cases has lesion in palm, 40% of the cases has lesion in 
trunk, 53% of the cases has lesion in  lower limb, 36.66% of the cases has lesion in face.  
CLINICAL IMPROVEMENT: 
               The Mean Standard Deviation of PASI Score before and after treatment was 20.66 
± 17.36 and 2.39 ± 3.7 respectively which is statistically significant (p < 0.0001).  
                The analysis reveals that there is 88% reduction in erythema, thickening of skin 
and scaling. 
  
156 
 
SUMMARY 
 Clinical Evaluation of Amukkara chooranam (Internal) and Vettiver thylam 
(External) for Kalanjaga padai(Psoriasis) in children was done after getting 
approved by IEC of National Institute of Siddha. [IEC No: NIS/IEC/2016/11-
17/14.10.2016] and the trial is registered in Clinical trial Registry of India with 
Reg.No CTRI /2017/06/008935 [Registered on: 29/06/2017]. 
 The raw drugs of Amukkara chooranam and Vettiver thylam were identified and 
authentication certificate was obtained.    
 The drug Amukkara choornam was a fine powder pale brownish in colour with 
strongly aromatic odour. 
 The drug  has a particle size with the range of lowest 46.63 µm to highest        163.3 
µm. The loss on drying indicates the moisture content of the drug was determined as 
8.3 ± 3.55%. The total ash was found to be 2.64 ± 0.25% which indicates the 
inorganic content of the drug. The water soluble ash was calculated as 11.87 ± 
2.99% and the value of acid insoluble ash was found to be 1.60 ± 0.03% which 
indicates that the drug contains negligible amount of siliceous matter. The water 
soluble extractive value and alcohol soluble extractive value were found to be 36.87 
± 1.72% and 36.9 ± 1.38%. The pH value is measured as 5  which indicates that the 
drug is weekly acidic.  
 HPTLC was done to identify phyto- chemicals and their Rf values were calculated.  
 The drug is free of microbial contamination and pesticide residues.  
 In heavy metals analysis mercury was not detected and lead, arsenic, cadmium were 
present within the permissible limit. 
 Aflatoxin like B2, G1, G2 were not detected except B1 which was within the 
permissible limit. 
 The disease Kalanjaga padai was taken for the clinical study with Amukkara 
chooranam (Internal) and Vettiver thylam (External) as a trial medicine and 30 cases 
were selected based on the approved protocol.  
 The detailed study of  Kalanjaga padai with reference to its etiology, pathogenesis,  
clinical features, diagnosis and treatment with trial drug was done. 
 The results were observed by PASI score. Among the 30 cases treated 60% of the 
cases had very good improvement and 23.33% had good improvement and 16.66% 
of the cases had moderate improvement. 
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 Statistical analysis:The Mean Standard Deviation of VASI Score before and after 
treatment was 20.66 ± 17.36 and 2.39 ± 3.75 respectively which is statistically 
significant (p < 0.0001).  
 The analysis reveals that there is 88% reduction in erythema , thickening of skin and  
scales.  
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    CONCLUSION 
 The poly herbal formulation Amukkara chooranam (Internal) and Vettiver thylam 
(External) exhibited no toxicity on short term administration in children.   
 The present clinical study confirms the efficacy and safety of the trial drug 
―Amukkara chooranam (Internal) and Vettiver thylam (External)‖ which are Siddha 
poly herbal formulations  respectively.  
 It was found to be having good result on Kalanjagapadai  patients in reducing 
clinical symptoms like erythema , thickening of skin , scaling.  
 The Mean Standard Deviation of PASI Score before and after treatment was 20.66 ± 
17.36 and 2.39 ± 3.7 respectively which is statistically significant (p < 0.0001). 
The analysis reveals that there is 88% reduction in erythema , thickening of skin , 
scling . 
 From the above results, the trial drug ―Amukkara chooranam (Internal) and Vettiver 
thylam (External)‖ provides  very good improvement in the treatment of Kaalanjaga 
padai. 
 The open clinical trial conducted on Kalanjaga padai with the trial drug Amukkara 
chooranam (Internal) and Vettiver thylam (External) creates a very good impact on 
the affected area. Hence the author recommends by increasing the trial period for 
about 90 days will bring out the tremendous effect of the drug in future which will 
reduce the stress of the affected children and enable to lead a healthy life. 
 As a conclusion it can be stated that the Siddha Herbal formulation Amukkara 
chooranam (Internal) and Vettiver thylam (External) can be used as a safe and 
extremely efficacious drug towards the management of Kalanjaga padai in children 
which takes a huge toll of inducing psychological stress and impact on the cosmetic 
purposes. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM (EXTERNAL)  FOR KALANJAGA PADAI                 
(PSORIASIS) IN CHILDREN. 
                                                      FORM  I- SCREENING   
1. S. No:    2. OP/ IP No:                           3.Name:          
4. Age:    5.Gender:   6.Date of Enrollment:       
7. Date of completion:   8.Informant:    9.Reliablity:    
INCLUSION CRETERIA                                                 YES                            NO 
  Age  between 5 to 12 years                               
  Erythema 
 Scaling 
 
  Itching  
                                               
 Thickness (Hyper keratinisation) 
 
 Auspitz sign  
 
 Candle grease sign  
 
 Dryness of the skin 
 
 Cracks  followed by itching 
 
 Willing to take photographs 
Whenever required with his/her consent 
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EXCLUSION CRITERIA                                                      YES            NO 
     Eczema 
    Fungal infection 
    systemic (cardiac ) involvement 
    Evidences of secondary infections in the lesions 
 ( Such as cellulitis ) 
   Psoriasis with evidence of any other 
              skin diseases  ( Seborrheic dermatitis, 
              Pustular Psoriasis ) 
 
Signature of HOD                                                Signature of Principal Investigator                                                         
                                                                                                             Sign of  Guide                    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM (EXTERNAL) FOR KALANJAGA PADAI                
(PSORIASIS) IN CHILDREN. 
FORM –II CONSENT FORM  
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent/guardian 
Signature  _________________ 
Date   _________________ 
Name  ________ _________  
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of 
the clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my son/daughter‘s  body function. 
 I am aware of my right to opt my son/daughter out of the trail at any time during the 
course of the trail without having to give the reasons for doing so.  
            I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial entitled Clinical Evaluation of Amukkara 
chooranam (internal) and Vettiver thylam (external) for Kalanjaga padai (psoriasis) in 
children. 
 
 
Date        Signature  
      Name    
Place      Signature of witness     
      Name    
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahj;jpjhr gz;bjH kUj;Jtkid>  nrd;id-47 
gl;lNkw;gbg;G Foe;ij kUj;Jtj;Jiw 
fhsQ;rfg; gil Neha;f;fhd mKf;fuh #uzk; (cs;shl;rp) kw;Wk; ntl;bNth; 
ijyk; (ntspahl;rp) ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;JtMa;T 
xg;Gjy; gbtk;  
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
ehd; ,e;j kUj;Jt Ma;it Fwpj;;J midj;J tpguq;fisAk; Nehahspapd; ngw;NwhUf;F 
GhpAk; tifapy; vLj;Jiuj;Njd; vd cWjp mspf;fpNwd;. 
Njjp:        ifnahg;gk;: 
,lk;:         ngah;:  
Nehahspapd; ngw;Nwhh; xg;Gjy;  
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;> kUe;jpd; jd;ik kw;Wk; kUj;Jt 
topKiwg; gw;wpAk;> ,e;j kUj;Jtj;ij njhlh;e;J vdJ Foe;ijapd; cly; ,af;fj;ijf; 
fz;fhzpf;fTk;> mjidg; ghJfhf;f gad;gLk; kUj;Jt Ma;Tfs; gw;wpAk; jpUg;jp mspf;Fk; 
tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ 
Ntz;LkhdYk; vd; Foe;ijia tpLtpj;Jf; nfhs;Sk; chpikia njhpe;jpUf;fpNwd;.  
ehd; vd;Dila Rje;jpukhf Njh;T nra;Ak; chpikiaf; nfhz;L fhsQ;rfg; gil 
Neha;f;fhd mKf;fuh #uzk; (cs;shl;rp) kw;Wk; ntl;bNth; ijyk; (ntspahl;rp) 
jpwid fz;lwpAk; kUj;Jt Ma;Tf;F vdJ Foe;ijia cl;gLj;j xg;Gjy; mspf;fpNwd;. 
Njjp:         ngw;nwhh; ifnahg;gk;: 
,lk;:        ngaH: 
        rhl;rpf;fhuu; ifnahg;gk;: 
        ngau;:  
          rhl;rpf;fhuu; cwTKiw 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM (EXTERNAL)  FOR KALANJAGA PADAI             
(PSORIASIS ) IN CHILDREN . 
  FORM  II A - ASSENT FORM (By Patient) 
                     I, _________________________ understand that my parents (mom and dad)/ 
guardian have/ has given permission (said it's okay) for me to take part in a clinical trial 
entitled Clinical evaluation of Amukkara Chooranam (Internal ) and Vettiver Thylam 
(external ) for  KALANJAGA PADAI (Psoriasis ) in Children done by PG Scholar  
Dr.M.Amala .     . 
         I am taking part because I want to take part. I have been told that I can stop at 
any time I want to do so and nothing will happen to me if I want to stop. 
 
  Date:                                                                             Signature of the patient 
                                                                                      
        Place:                                                                           Signature of Parent 
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Njrpa rpj;j kUe;Jt epWtdk; 
mNahj;jpjhr gz;bjH kUj;Jtkid> nrd;id-47 
gl;lNkw;gbg;G Foe;ij kUj;Jtj;Jiw 
fhsQ;rfg; gil Neha;f;fhd mKf;fuh #uzk; (cs;shl;rp) kw;Wk; ntl;bNth; 
ijyk; (ntspahl;rp) ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;T 
 
xg;Gjy; gbtk; Foe;ijf;fhdJ 
 ______________________ Mfpaehd; Njrpa rpj;j kUj;Jt epWtdj;jpy; gl;lNkw;gbg;G 
Foe;ij kUj;Jtj; Jiwapy; gapYk; kU.kh.mkyh mtu;fshy; elj;jg;gLk;; fhsQ;rfg; 
gil Neha;f;fhd mKf;fuh #uzk; (cs;shl;rp) kw;Wk; ntl;bNth; ijyk; 
(ntspahl;rp) ghpfhpg;Gj; jpwidf;; fz;lwpAk; kUj;Jt Ma;tpy; gq;Nfw;gjw;F vdJ 
ngw;NwhH fhg;ghsu; jpUjpUkjp.________________________rk;kjk; njuptpj;jpUg;gij ed;F mwpNtd;.  
 vdf;F ,e;j Muha;r;rp gw;wp; GhpAk; tifapy; vLj;Jiuf;fg;gl;Ls;sJ. 
,t;thuha;r;rpapy; ,Ue;J vg;NghJ Ntz;LkhdhYk; tpyf vdf;F chpik ,Uf;fpd;wJ 
vd;gij gw;wpAk; ed;F njupe;Jnfhz;L ,e;j Muha;r;rpapy; gq;Nfw;f rk;kjpf;fpNwd;.  
Njjp:       Foe;ijapd; ifnahg;gk; 
,lk;:        ngah; 
       ngw;nwhh;ifnahg;gk; 
       ngaH 
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                                        NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM (EXTERNAL)  FOR KALANJAGA PADAI                
(PSORIASIS) IN CHILDREN. 
FORM III CASE REPORT FORM 
Demographic data 
 Patient Id : OP/IP sNo. Visit Date : (__/__/____) 
Name   
Age      
Gender                Male             Female Date Of Birth : (__/__/____) 
Father/ Mother /Guardian Name   
 
Father‘s Occupation   
 
Father‘s Monthly  Income   
 
Religion  
 
 
 
Socioeconomic Status  
 
 
Patient Informant   
 
Relaibility  
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Postal Address 
 
 
 
 Contact No : 
 
 
COMPLAINTS AND DURATION            
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------ 
  HISTORY OF PRESENT ILLNESS  
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------ 
 
HISTORY OF PAST ILLNESS  
 _________________________________________________________________________ 
 
 Family History 
Any Hereditary/ Familial disease     Yes                      No 
 If Yes, Details --------------------------------------------------------------------------  
Family H/O similar condition        ------------------------------------------ 
 
Immunization History  
      Immunization  complete         Incomplete          Complete but time lag 
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Food habits 
Veg  Non-Veg   Mixed 
 
Personal Habits                                           Yes                  No  
Picca                                              
Nail biting               
Thumb sucking                         
Eneuresis                                   
Bowel (Regular)                  
 
General Examination                                Yes           No 
Pallor    
Jaundice      
Cyanosis      
Clubbing     
Pedal oedema      
Lymphadenopathy     
 
Vital signs 
Pulse rate / mint                - 
Heart rate / mint               - 
Respiratory Rate / mint    - 
Temperature                     - 
 
Anthropometry 
       Height     -               cm 
       Weight     -               kg          
Examination of Other systems                                 Normal                       Affected 
         Respiratory system                  
         Cardio vascular system                
         Gastro intestinal system              
         Musculo skeletal system                
         Central nervous system              
          Endocrine system                   
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SIDDHA ASSESSMENT 
Nilam  
            Kurinji  Mullai  Marutham      Neithal   Paalai 
Kaala Iyalbu  
 Kaarkalam    Koothirkaalam  Munpanikaalam  
 Pinpanikaalam            Illavenirkaalam          Muthuvenirkaalam 
  
Yaakai 
 Vatham          Vatha Pitham           Vatha Kabam 
 Pitham    Pitha vatham   Pitha Kabam 
 Kabam             Kaba Vatham   Kaba Pitham 
Gunam  
 Sathuvam   Rasatham   Thamasam 
Pori / Pulangal 
  Normal Affected  Normal Affected     Remarks 
Mei / unarvu 
Vaai / suvai  
Kan / parvai  
Mooku / natram 
Sevi / olli 
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Kanmendhirium / Kanmavidayam 
          Normal     Affected       Normal            Affected  Remarks 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaaku 
Eruvaai / visarkam 
Karuvaai / anantham 
Uyir Thathukkal 
Vatham1 
   Normal   Affected  Remarks 
Pranan  
Abanan 
Viyanan  
Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
Devathathan   
Dhanajeyan      
 
Pitham  
   Normal Affected  Remarks 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
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Kabam  
   Normal Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Santhigam  
Udalthathukkal 
   Normal Affected  Remarks 
Saaram 
Senneer  
Oon  
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
Envagai Thervugal  
Naa                         Normal  Affected  Remarks 
 Niram 
 Thanmai 
 Suvai 
Niram   
                                              Normal   Affected   
Mozhi  
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Vizhi  
 Niram 
 Thanmai 
 Paarvai 
Sparisam  
Malam                                             Normal             Affected 
 Niram     
 Nurai     
 Elagal    
 Erugal     
Moothiram 
 Neerkuri:       Niram     
  Edai      
  Nurai                
  Manam                
  Enjal      
Neikuri: 
  Vatham  
  Pitham 
  Kabam 
  Others 
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Naadi 
 
Clinical examination: 
Clinical examination of skin: 
              Before Treatment                After Treatment 
1.Site 
2.Shape:          Coin shape                            
            Irregular 
           Dispersed 
              Present               Absent                   Present           Absent 
3.Etythema:                                                                                                    
4:Macule:                                                                              
5.Papule:                                                                                                       
6.Nodule: 
7.Vesicle 
8.Pustule:   
9.Hypo /  
   Hyperpigmentation                                                                                                          
10.Itching:                        No 
         Mild 
         Moderate 
         Severe 
11.Scaling:      Mild 
       Moderate 
       Severe 
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         Present                Absent                Present              Absent 
12.Fissures:       
13.Oozing                 :        No 
         Mild 
         Moderate 
         Severe 
                                  Present                Absent                Present              Absent          
14.Lichenification: 
                                  Present                Absent                Present              Absent          
15.Auspitz sign:  
                                   Present                Absent                Present              Absent    
16.Kobner‘s 
      Phenomenon                                    
                                  Present                Absent                Present              Absent   
17.Candle 
      grease sign   
Examination of nails                                                Present                            Absent 
         Pitting          
         Thickening                     
         Collection of Hyperkeratotic debris                   
         Separation of distal portion of nail                   
Examination of joints                                                    Yes                               No 
         Joint Involvement                                         
Date:       Signature of Investigator 
Place:                                                                                        Signature of Guide 
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CLINICAL ASSESSMENT 
                                       
 
 
                                                             PASI Calculation 
Patient name   
Date   
Plaque Characteristic Rating Score 
Body region and weighting factor 
Head 
Upper 
Limbs 
Trunk 
Lower 
Limbs 
Erythema 0 = None         
Thickness 
1 = Slight 
        
2 = Moderate 
Scaling 
3 = Severe 
        4 = Very 
Severe 
 Totals A1= A2= A3= A4= 
Weighting Factor A1x0.1=B1 A2x0.2=B2 A3x0.3=B3 A4x0.4=B4 
Surface area totals B1= B2= B3= B4= 
  
Degree of 
involvement as  
% for each body 
region  
affected (score each  
region between 0 and 
6) 
0 = None 
    
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Surface area totals x % involvement 
totals 
Sum Scores above = 
B1xscore=
C1 
B2xscore=
C2 
B3xscore=
C3 
B4xscore=
C4 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM (EXTERNAL)  FOR KALANJAGA PADAI                   
(PSORIASIS) IN CHILDREN. 
FORM VI -DRUG COMPLIANCE FORM 
S. NO: ---------   OPD/IPD NO: --------------- NAME: -----------------------        REG NO:  
DAY Date Morning Evening 
I visit    1    
2    
3    
4    
5    
6    
7    
II visit      1                                              
2    
3    
4    
5    
6    
7    
III visit   1    
2    
3    
4    
5    
6    
7    
IV visit    1     
2    
3    
179 
 
4    
5    
6    
7    
V visit     1    
2    
3    
4    
5    
6    
7    
VI visit   1    
2    
3    
4    
5    
6    
7    
VII visit    1    
2    
3    
4    
5    
 
Date:                                                                                      Signature of the Investigator 
Place:                                                                                              Signature of the Guide                                                                                              
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM  (EXTERNAL)  FOR KALANJAGA PADAI               
(PSORIASIS) IN CHILDREN. 
 1.  S.No:    2. OP/ IP No:                           3.Name:   
 4.Age:       5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity:   
FORM VIII _-  WITHDRAWAL  
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal   : Yes/ No  
Long absence at reporting   : Yes/ No 
Irregular treatment     : Yes/ No 
Shift of locality      : Yes/ No 
Complication adverse reactions if any : Yes/ No 
Exacerbation of symptoms   : Yes/ No 
 Patient not willing to continue  : Yes/ No 
 
Date:       Signature of Principal Investigator 
Place:                                                                                   Signature of Guide  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM  (EXTERNAL)  FOR KALANJAGA PADAI               
(PSORIASIS) IN CHILDREN. 
 1.  S.No:    2. OP/ IP No:                           3.Name:   
 4.Age:       5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity:   
FORM VIII _-  WITHDRAWAL  
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal   : Yes/ No  
Long absence at reporting   : Yes/ No 
Irregular treatment     : Yes/ No 
Shift of locality      : Yes/ No 
Complication adverse reactions if any : Yes/ No 
Exacerbation of symptoms   : Yes/ No 
 Patient not willing to continue  : Yes/ No 
 
Date:       Signature of Principal Investigator 
Place:                                                                                   Signature of Guide  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF AMUKKARA CHOORANAM (INTERNAL) AND 
VETTIVER THYLAM (EXTERNAL) FOR KALANJAGA PADAI                  
(PSORIASIS) IN CHILDREN. 
1.  S. No:    2. OP/ IP No:                           3.Name: 
 4.Age:       5.Gender:   6.Date of Enrollment:       
7.  Date of completion: 8.Informant:    9.Reliablity 
   
                                     Form VII – ADVERSE REACTION FORM   
 
Name       : 
Age       : 
Gender    : 
OPD/ IPD No    : 
Registration No    : 
Date of trial commencement  : 
Date of withdrawal from trial   : 
Description of adverse reaction  : 
 
 
 Date :                                                                             Signature of  Investigator   
 Place :                                                                                     Signature of Guide 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR SIDDHA 
DRUGS 
 
 
 
Please note:  i. All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even if  
             it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of initial 
observation 
 Season: 
Description of reaction   
 
 Geographical area: 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the patient 
during the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for which 
medicine taken  
Starting Stopped 
Siddha 
 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and batch 
No. and date 
   
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the 
formulation / Part of the drug 
used 
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b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used as self 
medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction / side effect / untoward effects (please complete the boxes 
below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
186 
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / Manufacturer 
/                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
 
 
 
 
Signature of the reporter:       Date: 
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Please send the completed form to:  
            The Director 
             National Institute of Siddha, 
                                                                  (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                                   Tambaram Sanatorium, Chennai-600 047. 
                                                                    (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence of ADR   
 
 
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
        
Date:      
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                       Signature of the HOD 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for 
legal claim  
Name & address of the RRC-
ASU / PPC-ASU 


   
  
 
  
 
  
 
